Proteins containing the extracellular domain of P75NTR
Fusion proteins of the p75NTR extracellular domain with a half-life extending moiety address the limitations of existing pain treatments by effectively managing osteoarthritis pain in companion animals with reduced side effects and improved pharmacokinetic properties.
Patent Information
- Application Number
- JP2024523649
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-21
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-19
AI Technical Summary
Current pain relief treatments for companion animals, particularly dogs, are inadequate in effectively managing osteoarthritis-related pain with minimal side effects, as seen with non-steroidal anti-inflammatory drugs (NSAIDs) and monoclonal antibodies targeting nerve growth factor (NGF), which can cause joint degeneration and other adverse effects.
Development of fusion proteins comprising the extracellular domain of the p75 neurotrophin receptor (p75NTR) fused with a half-life extending moiety, such as an immunoglobulin Fc domain, to bind and regulate NGF levels, reducing pain without completely blocking NGF signaling.
The fusion proteins provide effective pain relief for companion animals by maintaining normal NGF signaling levels, demonstrating improved solubility, stability, and a prolonged half-life, reducing the frequency of administration and minimizing side effects.
Smart Images

Figure 2024542958000001_ABST
Abstract
Description
[Technical field]
[0001] RELATED APPLICATIONS AND INCORPORATION BY REFERENCE All documents cited or referenced herein ("documents cited herein"), and all documents cited or referenced in the documents cited herein, as well as any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein, or any documents incorporated by reference herein, are incorporated by reference herein and may be employed in the practice of the present invention. More specifically, all documents referenced are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
[0002] FIELD OF THEINVENTION The present invention relates to effective pain therapy in companion animals. [Background technology]
[0003] Overview There is a great need for therapies in veterinary medicine, particularly for pain relief.
[0004] Pain relief treatments for dogs currently include nonsteroidal anti-inflammatory drugs, commonly referred to as NSAIDs, and several nonsteroidal anti-inflammatory drugs that help control pain and inflammation associated with osteoarthritis. Several NSAIDs are approved by the FDA. However, there is a need for additional effective pain treatments in companion animals with minimal side effects.
[0005] Nerve growth factor (NGF) was first discovered in the 1950s. The NGF protein was subsequently cloned and identified as part of brain-derived neurotrophic factor (BDNF), neurotrophin 3 and 4 / 5 (NT-3, NT-4-5), all of which are secreted proteins that promote the survival and growth of the peripheral nervous system.
[0006] NGF induces peripheral sensitization both in vitro and in vivo, as shown by increased responses of DRG neurons to temperature or capsaicin in its presence. NGF also induces transcriptional regulation after retrograde axonal transport, as shown by immunostaining showing upregulation of BDNF after intrathecal NGF treatment. Furthermore, NGF can induce sprouting of peripheral afferents into diseased joints and cancer tissues (Denk et al, Annual Review of Neuroscience, Vol. 40: 307-325, 2017).
[0007] NGF is expressed at low levels in adulthood, but injury, inflammation, or release of NGF leads to activation of inflammatory cells. These cells then produce and secrete NGF in turn, resulting in short-term and long-term effects. NGF has a well-known multifunctional role in nociceptive processes, but the precise signaling pathways downstream of NGF receptor activation that mediate nociception are complex and incompletely understood. The role of NGF in nociception, as well as in the generation and / or maintenance of chronic pain, has made it an attractive target for pain therapy for the treatment of chronic pain conditions (Barker et al, Journal of Pain Research, 2020:13 1223-1241).
[0008] Very low doses of monoclonal antibodies (mAbs) against NGF can reduce chronic pain. However, during clinical trials in humans, a small number of patients treated with mAbs against NGF developed rapidly progressive joint degeneration due to interactions with NSAID treatment. Complete NGF ablation has been shown to cause impaired bone and cartilage repair (Denk et al, Annual Review of Neuroscience, Vol. 40: 307-325, 2017). Treatments for use in dogs and cats based on species-specific mAbs targeting NGF are currently under development for the management of osteoarthritis (OA)-associated pain (Enomoto et al, Vet Rec. 2019 Jan 5; 184 (1): 23 and WO2019177690). However, given the side effects that occurred in clinical trials in humans, there is a need to develop alternative treatments targeting NGF.
[0009] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention. Summary of the Invention
[0010] The present invention aims to address the need for effective pain therapy in companion animals.
[0011] The present invention provides a pain therapy for companion animals with reduced side effects compared to anti-NGF antibody therapy. The protein of the present invention binds to NGF, which is at elevated levels in pain conditions, and thus binds to excess NGF and restores normal NGF levels without completely blocking NGF signaling. Without wishing to be bound by theory, the inventors believe that this ensures the level of NGF signaling necessary for healthy function. Furthermore, the fusion protein of the present invention can operate at very low doses, but is believed to be highly effective.
[0012] The inventors use an analgesic strategy to reduce, but not completely deplete, circulating NGF. For this purpose, they used the extracellular domain (ECD) of the p75 neurotrophin receptor (p75NTR), fused to Fc to increase its half-life. p75NTR binds NGF and other brain-derived neurotrophic factors (NT3, NT4) and mediates different cellular activities.
[0013] The use of human p75 has been described for the treatment of pain in humans (WO2013136078).
[0014] Thus, in a first aspect, the invention relates to an isolated companion animal p75NTR protein or a portion thereof. The invention also relates to an isolated nucleic acid encoding the protein or a portion thereof.
[0015] The present invention also relates to a vector comprising the above-mentioned nucleic acid sequence.
[0016] The present invention relates to a host cell containing the above-described nucleic acid.
[0017] In another aspect, the invention relates to a fusion protein comprising an isolated companion animal p75NTR extracellular domain, or a portion thereof, and a half-life extending moiety.
[0018] In another aspect, the present invention relates to a nucleic acid encoding the above-mentioned fusion protein.
[0019] In another aspect, the present invention relates to a vector comprising the above-described nucleic acid.
[0020] In another aspect, the present invention relates to a host cell comprising the above-mentioned nucleic acid, or the above-mentioned vector.
[0021] In another aspect, the invention relates to a pharmaceutical composition comprising an isolated companion animal p75NTR protein as described above and herein, or a fusion protein as described above and herein.
[0022] In another aspect, the present invention relates to a method for treating an NGF-related disorder in a companion animal, comprising administering the isolated companion animal p75NTR protein described above, the fusion protein described above and herein, or the pharmaceutical composition described above and herein.
[0023] In another aspect, the invention relates to the use of the isolated companion animal p75NTR protein as defined above, the fusion protein as defined above, or the pharmaceutical composition as defined above and herein, in the treatment of an NGF-related disorder in a companion animal.
[0024] In another aspect, the present invention relates to a method of inhibiting NGF activity in a companion animal comprising administering an isolated companion animal p75NTR protein as described above, a fusion protein as described above and herein, or a pharmaceutical composition as described above and herein.
[0025] In another aspect, the present invention relates to a kit comprising the isolated companion animal p75NTR protein as described above, the fusion protein as described above, or the pharmaceutical composition as described above, and optionally instructions for use.
[0026] It is therefore an objective of the present invention not to include within the present invention any previously known product, process, or method of using a product, so that the applicant reserves the right and discloses a disclaimer of any previously known product, process, or method. It is further noted that the present invention is not intended to include within the scope of the present invention any product, process, or method of making a product, or method of using a product, that does not meet the written description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (Article 83 EPC), and as a result, the applicant reserves the right and thereby discloses a disclaimer of any previously described product, process of making a product, or method of using a product. In the implementation of the present invention, it may be advantageous to comply with Article 53(c) of the EPC and Articles 28(b) and (c) of the EPC Rules. All rights to expressly disclaim any embodiment that is the subject of any granted patent of the applicant, in the line of this application, or in any other line, or in any prior application of any third party, are expressly reserved. Nothing herein should be construed as a promise.
[0027] In this disclosure, and particularly in the claims and / or paragraphs, terms such as "comprises," "comprised," "comprising," and the like can have the meaning ascribed to them in U.S. patent law, e.g., they can mean "includes," "included," "including," and the like, and terms such as "consisting essentially of" and "consists essentially of" can have the meaning ascribed to them in U.S. patent law, e.g., they allow for elements not expressly recited, but exclude elements found in the prior art or that affect a basic or novel characteristic of the invention.
[0028] These and other embodiments are disclosed or are obvious from and are encompassed by the following detailed description.
[0029] The invention is described in the following non-limiting figures. [Brief description of the drawings]
[0030] [Figure 1a] Exemplary fusion proteins: (a) PetML119. [Figure 1b] An exemplary fusion protein (b) PetML122. [Figure 2a] a) Sequence alignment of a portion of the ECD of p75NTR used in the fusion protein of the invention. There is a very high similarity between species: dog vs. cat: 1 / 164 (>99% identity); dog vs. horse: 4 / 164 (97.6%); cat vs. horse: 5 / 164 (97%); dog vs. cow: 2 / 164 (98.8% identity). [Figure 2b] b) Sequence alignment of Fc regions (including CH3, CH2 and CH2-CH1 hinge) from different species / different isotypes. [Figure 3a] Purity of the isolated fusion protein. a) H-SEC. PetML119 appears to be highly pure by analytical size exclusion chromatography. [Figure 3b] Purity of the isolated fusion protein. b) H-SCX. Cation exchange chromatography showed the presence of one major species (approximately 80%) and two minor charge variants. [Figure 4a] Stability of PetML119. a) Tonset analysis. [Figure 4b] Stability of PetML119. b) Heat and chemical stress. [Figure 4c] Stability of PetML119. c) Freeze and thaw stress. [Figure 4d] Stability of PetML119. d) Thermostability. [Figure 4e] Stability of PetML119. e) Aggregation assay. [Figure 5a]Protein A binding. a) PetML119 Protein A binding. [Figure 5b] Protein A binding. b) PetML119 Protein A binding. [Figure 5c] Protein A binding. c) PetML122 Protein A binding. [Figure 5d] Protein A binding. d) PetML122 Protein A binding. [Figure 5e] Protein A binding. e) Bezimbetomab Protein A binding. Bezimbetomab is an anti-NGF IgG control. [Figure 5f] Protein A binding. f) Kinetics table. [Figure 6a] PetML119 canine FcRN binding. a) Canine FcRN binding PetML119. [Figure 6b] PetML119 mouse FcRN binding. b) Mouse FcRN binding PetML119. [Figure 6c] PetML119 dog and mouse FcRN binding. c) Affinity table of dog and mouse binding FcRN. [Figure 6d] PetML122 canine FcRN binding. d) Canine FcRN binding PetML122. [Figure 6e] PetML122 mouse FcRN binding. e) Mouse FcRN binding PetML122. [Figure 6f] PetML122 dog and mouse FcRN binding. f) Affinity table of dog and mouse FcRN binding. [Figure 7a] NGF binding. a) PetML119 binding to human NGF. [Figure 7b] NGF binding. b) PetML119 to rat NGF. [Figure 7c] NGF binding. c) Kinetic affinity table. [Figure 7d] NGF binding. d) Bezimbetomab binding to human NGF. [Figure 7e] NGF binding. e) Kinetic affinity table. [Figure 8a]TF-1 cell proliferation assay. TF-1 labeled with CFSE cell tracer at 2.5uM for 30min at RT. TF-1 was seeded at 104 cells / well in 96-well plates. Positive control: TF-1 cells in RPMI medium + 10% FBS + 10ng / mL hNGF 3 time points (t 2h, t 4d and t 7d). a) Activity of NGF: EC50 of 2ng / mL. [Figure 8b] TF-1 cell proliferation assay. TF-1 labeled with CFSE cell trace at 2.5uM for 30min at RT. TF-1 was seeded at 104 cells / well in 96-well plates. Positive control: TF-1 cells in RPMI medium + 10% FBS + 10ng / mL hNGF 3 time points (t 2h, t 4d and t 7d). b) Readout of TF-1 cell proliferation assay. [Figure 8c] TF-1 cell proliferation assay. TF-1 labeled with CFSE cell trace at 2.5uM for 30min at RT. TF-1 were seeded at 104 cells / well in 96-well plates. Positive control: TF-1 cells in RPMI medium + 10% FBS + 10ng / mL hNGF 3 time points (t 2h, t 4d and t 7d). c) TF-1 cell proliferation assay readout using PetML119, PetML122 and bedinvetomab. [Figure 9] In vivo model. [Figure 10a] Analgesic effect in vivo. a) 2 hours after IV treatment. [Figure 10b] In vivo analgesic effect. b) 3 days after IV treatment. [Figure 10c] In vivo analgesic effect. c) 11 days after IV treatment. [Figure 10d] In vivo analgesic effect. d) 18 days after IV treatment. [Figure 11a] Joint diameter and body weight. a) Joint diameter analysis. [Figure 11b] Joint diameter and body weight. b) Body weight analysis. [Figure 12a] pK analysis-half-life. a) Standard curve of PetML119 in rat serum. [Figure 12b] pk analysis-half-life. b) Standard curve of PetML122 in rat serum. [Fig. 12c-f] pK analysis - half-life. cf) pK results from rat studies. The calculated half-life of PetML119 at different concentrations is 56-70 hours. [Figure 13a] Safety analysis of PetML119 / PetML122 in dogs. a) Body weight. The top row in the table above shows the individual animals in group 1, and the bottom row in the table above shows the individual animals in group 2. Group 1 animals were treated with PetML119 and group 2 animals were treated with PetML122 (see Table 3). The bottom table shows the average values. [Figure 13b] Safety analysis of PetML119 / PetML122 in dogs. b) Anti-drug antibody (ADA) analysis. Top panel PetML119, bottom panel PetML120. [Figure 14] a-d: Efficacy analysis of PetML119 / PetML122 in dogs. Force plate analysis and visual lameness analysis of PetML119 / PetML122. [Figure 14a] Efficacy analysis of PetML119 in dogs. Force plate analysis of PetML119. [Figure 14b] Efficacy analysis of PetML119 in dogs. Visual lameness analysis of PetML119. [Figure 14c] Efficacy analysis of PetML122 in dogs. Force plate analysis of PetML122. [Figure 14d] Efficacy analysis of PetML122 in dogs. Visual lameness analysis of PetML122. [Figure 15a] Dog pk analysis - half-life. Above (a) shows the endpoint absorbance at 650 nm and 450 nm using serum. [Figure 15b] Dog pk analysis - half-life. (b) below shows a monophasic decay fit to estimate the half-life of PetML119 / PetML122. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] The present invention will now be further described. In the following paragraphs, different aspects of the present invention will be defined in more detail. Each aspect so defined can be combined with any other aspect or aspects, unless expressly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
[0032] In general, the nomenclature used in connection with, and techniques of, cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. Unless otherwise indicated, the methods and techniques of the present disclosure are generally carried out according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. See, for example, Green and Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012), Therapeutic Monoclonal Antibodies: From Bench to Clinic, Zhiqiang An (Editor), Wiley, (2009), and Antibody Engineering, 2nd Ed., Vols. 1 and 2, Ontermann and Duebel, eds., Springer-Verlag, Heidelberg (2010).
[0033] Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
[0034] The present invention provides biological therapeutics for veterinary use, particularly fusion proteins for use in the treatment of companion animals such as dogs, cats, cows, or horses.
[0035] In a first aspect, the present invention relates to an isolated companion animal p75NTR protein or portion thereof.
[0036] As used herein, the term p75NTR protein refers to p75NTR protein that binds NGF and / or other neurotrophins (BDNF, NT-3 and / or NT-4 / 5). As used herein, this means that the protein can bind to NGF and inhibit NGF biological activity and / or downstream pathways mediated by NGF signaling. NGF binding protein reduces NGF biological activity, including downstream pathways mediated by NGF signaling, and / or reduces the amount of NGF in circulation that can bind to its receptors trkA and NGFR (p75NTR).
[0037] As used herein, the term "companion animal" refers to a dog, cat, or horse. In one embodiment, the companion animal is a dog. In another embodiment, the animal being treated may be a cow or a pig.
[0038] The term "isolated" protein or polypeptide refers to a protein or polypeptide that is substantially free of other proteins or polypeptides with different antigenic specificities. Furthermore, the protein or polypeptide will be substantially free of other cellular material and / or chemicals. Thus, the proteins, nucleic acids, and polypeptides described herein are preferably isolated. Thus, as used herein, an "isolated" protein or polypeptide refers to a protein or polypeptide that has been identified, separated, and / or recovered from components of its natural cell culture environment. Contaminating components of its natural environment are substances that would interfere with diagnostic or therapeutic uses for the protein or polypeptide, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
[0039] The terms "polypeptide" and "protein" are used interchangeably and refer to a polymer of amino acid residues and are not limited to a minimum length. Peptides, oligopeptides, dimers, multimers, etc., composed of amino acids arranged in a linear chain linked by peptide bonds, whether produced biologically, recombinantly, or synthetically, and whether composed of naturally occurring or non-naturally occurring amino acids, are also included in the definition. Both full-length proteins and fragments thereof are encompassed by the definition. These terms also include co-translational and post-translational modifications of the polypeptide, such as, for example, disulfide bond formation, glycosylation, acetylation, phosphorylation, proteolytic cleavage (e.g., cleavage by furin or metalloproteases and prohormone convertases (PC)). Furthermore, for purposes of the present invention, "polypeptide" encompasses proteins containing modifications, such as deletions, additions, and substitutions (which are generally conservative in nature, as known to those of skill in the art) to the native sequence, so long as the protein maintains the desired activity. These modifications may be deliberate, as by site-directed mutagenesis, or may be accidental, such as by mutations of hosts which produce the proteins or errors during PCR amplification or other recombinant DNA methods. Polypeptides or proteins are composed of linearly arranged amino acids linked by peptide bonds but, in contrast to peptides, have a well-defined conformation.
[0040] In contrast to peptides, proteins generally consist of a chain of 50 or more amino acids. For the purposes of the present invention, the term "peptide" as used herein refers to a sequence of amino acids that typically consists of a single chain of D- or L-amino acids, or a mixture of D- and L-amino acids linked by peptide bonds. Generally, peptides contain at least two amino acid residues and are less than about 50 amino acids in length.
[0041] By "amino acid" herein is meant one of the 20 naturally occurring amino acids or any non-natural analogues that may be present at a particular defined position. Amino acid encompasses both naturally occurring and synthetic amino acids. However, in most cases, only naturally occurring amino acids are used when proteins are produced recombinantly.
[0042] In one embodiment, the isolated companion animal p75NTR protein comprises or consists of a canine, feline or bovine p75NTR protein or a portion or variant thereof. Thus, in one embodiment, the isolated companion animal p75NTR protein comprises or consists of SEQ ID NO: 1, 3, 5 or 36, a portion or variant thereof, or a partial variant.
[0043] The native form of the p75 neurotrophin receptor, p75NTR, exists as a transmembrane glycoprotein. Family members are characterized by multiple cysteine-rich domains for ligand binding, a single transmembrane sequence, an extracellular domain (ECD), and a non-catalytic cytoplasmic domain.
[0044] The endogenous soluble ECD of p75NTR is generated by α- and γ-secretase-regulated proteolysis that cleaves the protein near the membrane junction of the ECD, a cleavage that results in the release of the cytoplasmic domain that is free to bind NGF as a natural antagonist for NGF signaling.
[0045] In one embodiment, the isolated companion animal p75NTR protein or a portion thereof comprises or consists of the extracellular domain (ECD), or a portion or variant thereof. In one embodiment, the isolated companion animal p75NTR protein or a portion thereof comprises or consists of the extracellular domain (ECD). In one embodiment, the isolated companion animal p75NTR protein or a portion thereof comprises the extracellular domain (ECD) of the companion animal p75NTR protein and additional C-terminal amino acids adjacent to the ECD. For example, the portion of the companion animal p75NTR protein may include the ECD and at least 1 to 5 or 5 to 10 amino acids of the companion animal p75NTR protein adjacent to the ECD, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C-terminal amino acids, or the ECD and at least 10 to 20 amino acids, or the ECD and at least 20 to 30 amino acids, or the ECD and at least 30 to 40 amino acids, or the ECD and at least 40 to 50 amino acids, or the ECD and at least 50 to 60 amino acids, or the ECD and at least 60 to 70 amino acids, or the ECD and at least 70 to 80 amino acids, or the ECD and and at least 80 to 90 amino acids, or the ECD and at least 90 to 100 amino acids, or the ECD and at least 100 to 110 amino acids, or the ECD and at least 110 to 120 amino acids, or the ECD and at least 120 to 130 amino acids, or the ECD and at least 130 to 140 amino acids, or the ECD and at least 140 to 150 amino acids, or the ECD and at least 150 to 160 amino acids, or the ECD and at least 160 to 170 amino acids, or the ECD and at least 170 to 180 amino acids of the companion animal p75NTR protein adjacent to the ECD.
[0046] In one embodiment, the alpha-secretase and gamma-secretase cleavage sites in the ECD are deleted. In one embodiment, the stalk region is deleted. In one embodiment, the stalk region and the alpha-secretase and gamma-secretase cleavage sites in the ECD are deleted.
[0047] In one embodiment, the isolated companion animal p75NTR extracellular domain is from a dog and comprises or consists of SEQ ID NO:7 or a variant or portion thereof, such as SEQ ID NO:34.
[0048] In another embodiment, the isolated companion animal p75NTR extracellular domain is from a feline and comprises or consists of SEQ ID NO: 38, or a variant or portion thereof.
[0049] The ECD of p75NTR has a stalk region (e.g., SEQ ID NO: 9, canine stalk region) that is prone to O-glycosylation. Glycosylation in proteins can cause manufacturing difficulties. Thus, in one embodiment, the isolated companion animal ECD can include deletions in the stalk region to reduce the number of O-glycosylation sites in the stalk region, for example, to form a truncated stalk region. The truncated stalk region can include any number of amino acids of the stalk region. For example, the stalk region can include 1-10, 1-20, 1-30 amino acids. The stalk region can be removed in embodiments of the fusion proteins described herein. Thus, as used herein, a portion of the ECD can be an ECD without the stalk region and the 3' sequence alpha-secretase and gamma-secretase cleavage sites (e.g., canine sequence SEQ ID NO: 34).
[0050] Thus, in one embodiment, the isolated companion animal p75NTR is a truncated protein in which the O-glycosylated stalk region has been removed.
[0051] In one embodiment, the isolated companion animal p75NTR protein may be a variant of the wild-type protein that contains one or more amino acid modifications compared to the wild-type protein. The modifications may be amino acid substitutions, deletions, or additions.
[0052] By "variant" or "mutant" herein is meant a polypeptide sequence that differs from that of a wild-type sequence by at least one amino acid modification. As used herein, "substitution of an amino acid residue" by another amino acid residue in the amino acid sequence of a protein or polypeptide described herein is equivalent to "replacing an amino acid residue" by another amino acid residue, and indicates that a particular amino acid residue at a particular position in the original (e.g., wild-type / germline) amino acid sequence has been replaced (or substituted) by a different amino acid residue. This can be done using standard techniques available to those skilled in the art, e.g., recombinant DNA techniques. Amino acids are altered compared to the native (wild-type / germline) sequence as found in nature in wild-type (wt), but can also be made in IgG molecules that contain other changes compared to the native sequence.
[0053] As used herein, a variant of the p75NTR protein or a portion thereof retains the biological function of the wild-type protein of binding to NGF.
[0054] Amino acid modification generally refers to and includes substitution, insertion, and deletion, with the former being preferred in many cases. Variants of the present invention include amino acid substitutions, and as described herein, they can include any number of further modifications, so long as the function of the protein is still present. In one embodiment, generally, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modifications are generally utilized, since it is often the goal to change the function with a minimum number of modifications. The variant polypeptide sequence preferably has at least about 80%, 85%, 90%, 95%, or up to 98% or 99% identity to the wild-type or parent sequence. It should be noted that the identity percentage depends on the number of amino acids, depending on the size of the sequence. Variants do not include human sequences.
[0055] By "protein variant" or "variant protein" herein is meant a protein that differs from a wild-type protein by at least one amino acid modification. The parent polypeptide may be a naturally occurring or wild-type (WT) polypeptide, or may be a modified version of a WT polypeptide. A variant polypeptide may refer to the polypeptide itself, a composition comprising the polypeptide, or the amino acid sequence encoding it. Preferably, a variant polypeptide has at least one amino acid modification compared to the parent polypeptide, e.g., about 1 to about 10 amino acid modifications compared to the parent, preferably about 1 to about 5 amino acid modifications. The variant polypeptide sequence herein preferably has at least about 80% identity, and most preferably at least about 90% identity, more preferably at least about 95% identity, to the parent polypeptide sequence. Variants do not include human sequences.
[0056] As used herein, "parent polypeptide" or "parent protein" refers to an unmodified polypeptide that is subsequently modified to generate a variant. The parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide. The parent polypeptide may refer to the polypeptide itself, a composition that includes the parent polypeptide, or the amino acid sequence that encodes it.
[0057] As used herein, "wild-type" or "WT," "wt," or "native" refers to an amino acid or nucleotide sequence found in nature, including allelic variations. A WT protein, polypeptide, Fc domain, immunoglobulin, etc., has an amino acid or nucleotide sequence that has not been intentionally modified.
[0058] In another aspect, the present invention relates to an isolated nucleic acid encoding a companion animal p75NTR protein or a portion thereof, such as an ECD or a portion thereof or a variant. As used herein, a portion of p75NTR or a portion of the ECD of p75NTR comprises at least one neurotrophin binding domain. In one embodiment, the companion animal is a dog. For example, the isolated nucleic acid comprises or consists of SEQ ID NO: 2, 4, 6, 8 or 37, or a variant or a portion thereof.
[0059] By "isolated nucleic acid molecule" is meant DNA or RNA of genomic, mRNA, cDNA, or synthetic origin, or some combination thereof, where the isolated polynucleotide is not associated with all or a portion of a polynucleotide found in nature, or where the isolated polynucleotide is linked to a polynucleotide with which it is not linked in nature.
[0060] In another aspect, the invention relates to a vector, plasmid, transcription, expression cassette or nucleic acid construct comprising a nucleic acid encoding a companion animal p75NTR protein or a portion thereof, such as an ECD or a portion thereof as described above.
[0061] The construct may include a suitable leader sequence. The term leader sequence is used interchangeably with signal sequence. Thus, in some embodiments, the nucleic acid sequence / nucleic acid construct encoding the fusion protein may also include a leader sequence. The leader sequence is made as part of the protein and is cleaved off when the protein is secreted. Any suitable leader sequence may be used, including the endogenous p75 leader of the relevant species (e.g., canine, equine, feline, bovine), the endogenous p75 leader of a different species (e.g., human, canine, equine, feline, bovine or mouse IgG leader), or another leader sequence known in the art, e.g., a natural immunoglobulin germline leader sequence, such as the Campath leader sequence (see US 8,362,208 B2), or an artificial sequence. Such leader sequences may help enhance protein expression.
[0062] In another aspect, the invention relates to a host cell comprising a nucleic acid encoding a companion animal p75NTR protein or a portion thereof, such as an ECD, or a vector, plasmid, vector, transcription or expression cassette or construct as described above.
[0063] Expression vectors for use in the present invention can be constructed from a starting vector, such as a commercially available vector. After the vector is constructed and the nucleic acid molecule is inserted into the appropriate site in the vector, the completed vector can be inserted into a suitable host cell for amplification and / or polypeptide expression.
[0064] The term "vector" refers to a construct capable of delivering, and in some embodiments expressing, one or more genes or sequences of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and eukaryotic cells such as producer cells.
[0065] The present invention also relates to an isolated recombinant host cell comprising one or more of the nucleic acid molecule plasmids, vectors, transcription or expression cassettes described above. Transformation of the expression vector into the selected host cell can be accomplished by known methods, including transfection, infection, calcium phosphate co-precipitation, electroporation, microinjection, lipofection, DEAE-dextran mediated transfection, or other known techniques. The method selected will be, in part, a function of the type of host cell used.
[0066] The host cell can be a eukaryotic or prokaryotic cell, such as a bacterial, viral, plant, fungal, mammalian, or other suitable host cell. In one embodiment, the cell is an E. coli cell. In another embodiment, the cell is a yeast cell. In another embodiment, the cell is a Chinese Hamster Ovary (CHO) cell, a HeLa cell, or other cells that will be apparent to one of skill in the art. Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, immortalized cell lines available from the American Type Culture Collection (ATCC), and any cell line used in expression systems known in the art can be used to produce the recombinant polypeptides of the invention.
[0067] Generally, host cells are transformed with recombinant expression vectors containing DNA encoding the protein. Among the host cells that can be used are prokaryotes, yeast or higher eukaryotic cells. Prokaryotes include gram-negative or gram-positive organisms, such as E. coli or Bacillus. Higher eukaryotic cells include insect cells and established cell lines of mammalian origin. Examples of suitable mammalian host cell lines include COS-7 cells, L cells, CI27 cells, 3T3 cells, Chinese hamster ovary (CHO) cells, or their derivatives, and related cell lines growing in serum-free medium, HeLa cells, BHK cell lines, CVIIEBNA cell lines, human embryonic kidney cells such as 293, 293 EBNA or MSR 293, human epidermal A431 cells, human Colo205 cells, other transformed primate cell lines, normal diploid cells, cell lines derived from in vitro culture of primary tissues, primary explants, HL-60, U937, HaK or Jurkat cells. Optionally, mammalian cell lines such as, for example, HepG2 / 3B, KB, NIH 3T3, or S49 can be used for expression of the polypeptides when it is desired to use the polypeptides in various signal transduction or reporter assays.
[0068] Other suitable host cells include insect cells, plant cells, transgenic plants and animals using expression systems such as baculovirus, viruses and nucleic acid vectors.
[0069] Alternatively, it is possible to produce the polypeptides in lower eukaryotes such as fungal cell lines and yeasts, or in prokaryotes such as bacteria. Suitable yeasts include S. cerevisiae, S. pombe, Kluyveromyces strains, Pichia pastoris, Candida, or any yeast strain capable of expressing a heterologous polypeptide. Suitable bacterial strains include E. coli, Bacillus subtilis, S. typhimurium, or any bacterial strain capable of expressing a heterologous polypeptide. When proteins are made in yeast or bacteria, it may be desirable to modify the product produced therein, for example by phosphorylation or glycosylation of appropriate sites, to obtain a functional product. Such covalent attachments can be achieved using known chemical or enzymatic methods.
[0070] Host cells, when cultured under appropriate conditions, can be used to express a protein, which can then be collected from the culture medium (if the host cells secrete it into the medium) or directly from the host cells (if it is not secreted). Selection of an appropriate host cell depends on a variety of factors, including the desired expression level, polypeptide modifications desired or necessary for activity (such as glycosylation or phosphorylation), and the ease of folding into a biologically active molecule.
[0071] In another aspect, the present invention also relates to the use of the above-mentioned isolated companion animal p75NTR protein or a portion thereof as a fusion protein with another moiety, for example a half-life extending moiety as described in more detail below. Thus, the p75NTR protein or a portion thereof may be provided covalently bound or coupled to a half-life extending moiety. Alternatively, it may be provided incorporated into a liposome. The present invention further relates to an isolated companion animal p75NTR protein or a portion thereof for use in therapy. Further provided is an isolated companion animal p75NTR protein or a portion thereof for use in the treatment of pain-related disorders. Such disorders are described in more detail below.
[0072] In some embodiments, the half-life of the p75NTR protein is extended to improve its pharmacokinetic (PK) properties.
[0073] Fusion proteins Thus, in another aspect, the invention relates to a fusion protein comprising an isolated companion animal p75NTR protein or a portion thereof, such as the extracellular domain described above, and another portion.
[0074] For example, the other moiety may be a half-life extending moiety. Thus, the p75NTR protein or a portion thereof is coupled to a half-life extending moiety. As mentioned above, the p75NTR protein or a portion thereof may be of canine, feline or equine origin. Thus, the p75NTR protein or a portion thereof used in the fusion protein may comprise or consist of a sequence selected from SEQ ID NO: 1, 3, 5, 7, 34, 36 or 38, or a portion or variant thereof. In one embodiment of the canine p75NTR protein or portion, the stalk region (e.g., SEQ ID NO: 9) is removed.
[0075] Half-life extending moieties have been described previously. For example, the half-life extending moiety may be selected from the following non-limiting list: companion animal immunoglobulin Fc domain, polyethylene glycol (PEG), PEG derivatives, simple lipids, lipid dicarboxylic acids, lipids with additional moieties, companion animal serum albumin binding agents, such as small molecule binding agents or antibodies / antibody fragments that bind companion animal serum albumin, companion animal serum albumin, or the albumin binding domain (ABD) of streptococcal protein G. Examples of lipids include glucagon-like peptide 1 (GLP-1), analogs GLP-1 liraglutide, and semaglutide or cholesterol. Advantageously, using an immunoglobulin Fc domain facilitates purification of the protein. In particular, Fc binding to protein A may be used in the purification procedure. The presence of an immunoglobulin Fc domain may also stabilize the overall folding of the fusion protein and extend its half-life.
[0076] In one embodiment where the half-life extending moiety is a companion animal Fc domain, a companion animal serum albumin binding factor, or a companion animal serum albumin, the p75NTR protein or portion and the half-life extending moiety are derived from / specific to the same companion animal. For example, in one embodiment, the half-life extending moiety is a companion animal Fc domain of the corresponding companion animal. For example, if the p75NTR protein or portion thereof, e.g., the extracellular domain, is derived from a dog, the Fc domain is a dog-derived Fc domain. If the p75NTR protein or portion thereof, e.g., the extracellular domain, is derived from a cat, the Fc domain is a feline-derived Fc domain. If the p75NTR protein or portion thereof, e.g., the extracellular domain, is derived from a horse, the Fc domain is a horse-derived Fc domain. If the p75NTR protein or portion thereof, e.g., the extracellular domain, is derived from a cow, the Fc domain is a cow-derived Fc domain.
[0077] However, given the high sequence similarity between companion animal p75 proteins, in another embodiment, when the half-life extending moiety is a companion animal Fc domain, a companion animal serum albumin binding factor, or a companion animal serum albumin, the p75NTR protein or portion and the half-life extending moiety are not derived / specific from the same companion animal. For example, in one embodiment, the half-life extending moiety is a companion animal Fc domain of the corresponding companion animal, but the p75 protein or portion thereof is from a different companion animal. For example, for the treatment of dogs, when the Fc domain is an Fc domain from a dog, the p75NTR protein or portion thereof, such as the extracellular domain, may be derived from a different animal, such as a cat, horse, or cow. For example, for the treatment of cats, if the Fc domain is a feline Fc domain, the p75NTR protein or a portion thereof, e.g., the extracellular domain, can be derived from a different animal, e.g., dog, cow, or horse. For example, for the treatment of cats, if the Fc domain is a horse Fc domain, the p75NTR protein or a portion thereof, e.g., the extracellular domain, can be derived from a different animal, e.g., cat, cow, dog. In yet another embodiment, human p75 or a portion thereof fused to a companion animal Fc can be used.
[0078] The companion animal serum albumin binding agent, e.g., an antibody or fragment thereof, may be canine-derived or caninized, feline-derived or felineized, equine-derived or equine-ized, The companion animal serum albumin binding agent may bind to canine, feline, or equine serum albumin.
[0079] In one embodiment, the half-life extending moiety is a wild-type or variant Fc domain. The term variant is as defined above. For example, the Fc domain variant may have an altered half-life compared to the wild-type Fc domain. In one embodiment, the Fc domain is a canine Fc domain, i.e., a wild-type domain or a variant thereof. Variant Fc domains are described, for example, in WO2020 / 142625.
[0080] As used herein, "Fc" or "Fc region" or "Fc domain" refers to a polypeptide comprising the constant region of an antibody excluding the first constant region immunoglobulin domain (CH1), and optionally a portion of the hinge. In one embodiment, the Fc domain comprises constant region immunoglobulin domains CH2, CH3, and the hinge region between CH1 and CH2, or a portion of the hinge region.
[0081] Proteolytic digestion of antibodies releases different fragments called Fv (fragment variable), Fab (fragment antigen binding), and Fc (fragment crystallinity). The Fc fragment contains the carboxy-terminal portions of both H chains held together by disulfides. The constant domains of the Fc fragment are responsible for mediating the effector functions of the antibody.
[0082] In dogs, there are four IgG heavy chains, designated A, B, C, and D. These heavy chains represent four different subclasses of canine IgG, designated IgG-A, IgG-B, IgG-C, and IgG-D. The DNA and amino acid sequences of these four heavy chains were first identified by Tang et al. (Vet. Immunol. Immunopathol. 80:259-270 (2001)). Exemplary amino acid and DNA sequences for these heavy chains are also available from the GenBank database (IgGA: Accession No. AAL35301.1, IgGB: Accession No. AAL35302.1, IgGC: Accession No. AAL35303.1, IgGD: Accession No. AAL35304.1). The amino acid sequences of IgG-A, IgG-B, IgG-C, and IgG-D used by the inventors and in accordance with aspects and embodiments of the present invention are provided as SEQ ID NOs: 15, 16, 17, 18).
[0083] In humans, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains. For IgA and IgM, Fc may include the J chain. For IgG, the Fc domain includes immunoglobulin domains CH2 and CH3 and the lower hinge region between CH1 and CH2. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to include residues C226 or P230 at its carboxy terminus, with numbering according to the EU index as in Kabat.
[0084] As used herein, Fc may refer to an Fc region alone, or to this region in the context of an Fc fusion (a "fusion construct" or "fusion construct"), as described herein. An Fc domain may include all or a portion of an Fc region, i.e., N- or C-terminal sequences may be removed from a wild-type or variant Fc domain as long as they do not affect function.
[0085] Briefly, IgG function is generally achieved through interactions between the Fc region of Ig and Fcγ receptors (FcγR) or another binding molecule, sometimes on effector cells. This can trigger effector cells to kill target cells to which the antibodies are bound through their variable (V) regions. Antibodies against soluble antigens can also form immune complexes that are targeted to cγRs, resulting in the uptake of this immune complex (opsonization) or the induction of effector cells and the release of cytokines.
[0086] As used herein, "Fc gamma receptor," "FcγR," or "Fc gamma R" means any member of a family of proteins that binds the IgG antibody Fc region and are encoded by the FcγR gene.
[0087] In humans, three classes of FcγR have been characterized, although the situation is further complicated by the occurrence of multiple receptor forms. The three classes are: (i) FcγRI (CD64), which includes the isoforms FcγRIa, FcγRIb, and FcγRIc, binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, and occasionally neutrophils and eosinophils; (ii) FcγRII (CD32) binds complexed IgG with medium to low affinity and is widely expressed. These receptors can be divided into two important types, FcγRIIa and FcγRIIb. The "a" form of the receptor is found on many cells involved in killing (e.g., macrophages, monocytes, neutrophils) and appears to be able to activate the killing process, and occurs as two alternative alleles. The "b" form appears to play a role in inhibitory processes and is found on B cells, macrophages, as well as mast cells and eosinophils. On B cells, the "b" form appears to function to suppress further immunoglobulin production and isotype switching, for example to the IgE class. On macrophages, the b form acts to inhibit phagocytosis as mediated through FcγRIIa. On eosinophils and mast cells, the b form may serve to suppress activation of these cells by binding IgE to its distinct receptor. (iii) FcγRIII (CD16) binds IgG with intermediate to low affinity and exists as two types: FcγRIIIa is found on NK cells, macrophages, eosinophils, and some monocytes and T cells, and mediates ADCC; FcγRIIIb is highly expressed on neutrophils. Both types have distinct allotypic morphologies.
[0088] Canine Fc receptors are described in Bergeron et al. LM Bergeron et al.; Veterinary Immunology and Immunopathology 157(2014)31-41. Dogs have RI, RIIb, and RIII, but not RIIa.
[0089] In addition to binding to FcγR, IgG antibodies can activate complement, which can also result in cell lysis, opsonization, or cytokine release and inflammation. The Fc region also mediates properties such as transport of IgG to the neonate (via the so-called "FcRn"), increased half-life (also thought to be mediated via FcRn-type receptors), and autoaggregation. The Fc region is also responsible for interactions with Protein A and Protein G (which appear to be similar to the binding of FcRn).
[0090] As used herein, "effector function" refers to a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include, but are not limited to, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).
[0091] In one embodiment, the companion animal p75NTR protein or portions thereof, such as the extracellular domain and other portions, are linked or otherwise conjugated, attached, or covalently or non-covalently linked to a linker moiety. Suitable linkers are known to those of skill in the art. For example, the linker may be a peptide linker, such as a glycine and / or alanine and / or threonine and / or serine rich linker, e.g., (G4S) n and the like, where n is 1-4.
[0092] In another embodiment, the linker may be cleavable.
[0093] In one embodiment, the companion animal p75NTR protein or portion thereof comprises or consists of a canine p75NTR ECD or portion thereof. In one embodiment, the ECD comprises of consists of SEQ ID NO: 7 or a variant thereof.
[0094] Thus, in one embodiment, the invention relates to a fusion protein comprising a canine p75NTR ECD linked to a canine Fc domain, hi one embodiment, the ECD comprises or consists of SEQ ID NO: 7 or a variant thereof.
[0095] In one embodiment, the fusion proteins of the invention preferably bind to any one or more of NGF, BDNF, NT3, or NT4 / 5 with a binding affinity (Kd) of about 1 pM to about 100 nM. In some preferred embodiments, the binding affinity (Kd) is from about 5 pM to any of 10 pM, 20 pM, 40 pM, 50 pM, 100 pM, 0.2 nM, 0.5 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM, 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 35 nM, 40 nM, 45 nM, 50 nM, or 100 nM, as measured in an in vitro binding assay for NGF, BDNF, NT3, or NT4 / 5 as described herein. The subnanomolar range is preferred.
[0096] In one embodiment, the fusion protein comprises or consists of SEQ ID NO: 11 or 13 or variants thereof. These fusion proteins comprise p75 ECD operably linked to a canine Fc domain as shown in FIG. 1. The Fc domain in the construct of SEQ ID NO: 11 is a wild type canine Fc domain. The Fc domain in the construct of SEQ ID NO: 13 is a variant canine Fc domain that has been modified to increase half-life. In this domain, the mutation YTE has been introduced at residues Y252 to T254 of the wild type Fc domain, using EU numbering.
[0097] In another embodiment, the fusion protein comprises or consists of SEQ ID NO: 39. Such a fusion protein comprises a p75 ECD operably linked to a feline Fc domain. The Fc domain in the construct of SEQ ID NO: 39 is a wild type feline Fc domain.
[0098] Thus, modified companion animal Fc domains, such as canine, feline or equine Fc domains, containing this mutation may be used in the fusion proteins of the invention. Those skilled in the art will know that any other known mutation that increases half-life may also be introduced into the Fc domain.
[0099] According to the present invention, the fusion protein exhibits advantageous biological properties, including improved solubility, stability, and / or improved serum half-life. Improved solubility and stability are demonstrated, for example, in Examples 4 and 9. These examples show that the described molecules are very stable both in temperature and chemical stress, showing unfolding only when incubated at temperatures above 70°C, and do not aggregate up to 95°C, with a Tm1 of around 67°C. Improved half-life is demonstrated, for example, in Examples 11 and 12. Improved half-life allows for less frequent dosing (single administration compared to existing treatments, which require daily administration). This effect is demonstrated by a strong analgesic effect.In one embodiment, the fusion protein of the invention has a length of about 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 1 58, 160, 62, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, or 210 hours ± 1 hour, or 2, 4, 6, 8, 10, 12, 14, 16, 18 , 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 1 10, 1 12, 1 14, 1 16, 1 and more preferably, the p75NTR(NBP)-Fc fusion proteins of the present invention have an in vivo half-life of about or greater than 24 hours.
[0100] In another embodiment, the fusion protein of the invention is about 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 1 22, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 62, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208 or 210 days ± 1 day, or 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144 , 146, 148, 150, 152, 154, 156, 158, 160, 62, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, or 210 days ± 1 day, and further, the fusion protein has an in vitro half-life of about or greater than 6 days, or greater than 1 month. In one embodiment, the half-life is 14 days.
[0101] According to the aforementioned preferred embodiment, the in vivo half-life may be the half-life in a rat or a corresponding companion animal, such as a dog.
[0102] The fusion proteins of the invention can operate at very low doses, but are highly effective, as demonstrated, for example, in Examples 11 and 12, where administration of PetML119 and PetML122 in rats and dogs outperforms existing treatments.
[0103] According to the present invention, the fusion protein exhibits a good safety profile. This is shown, for example, in Example 12, where animals maintain normal body weight and hematological parameters and do not develop anti-drug antibodies after administration of the fusion protein. Maintenance of normal body weight after administration is also shown, for example, in Example 11. This is in contrast to administration of dexamethasone, which resulted in weight loss over time.
[0104] In another aspect, the invention relates to an isolated nucleic acid encoding the fusion protein described above, e.g., a fusion protein encoding SEQ ID NO: 11, 13 or 39. In one embodiment, the nucleic acid is selected from SEQ ID NO: 12, 14 or 40.
[0105] In another aspect, the invention relates to a vector, a plasmid, a vector, a transcription or expression cassette or a construct comprising the above-mentioned nucleic acid.
[0106] In another aspect, the present invention relates to a host cell comprising the above-mentioned nucleic acid vector, plasmid, vector, transcription or expression cassette, or construct. Suitable host cells are described elsewhere herein.
[0107] In another embodiment, the P75NTR protein, a portion thereof, or a fusion protein is labeled with a detectable or functional label. The label can be any molecule that produces a signal or can be induced to produce a signal, including, but not limited to, a fluorophore, a fluorescent substance, a radioactive label, an enzyme, a chemiluminescent substance, a nuclear magnetic resonance active label, or a photosensitizer. Thus, binding can be detected and / or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity, or light absorbance.
[0108] In another aspect, a pharmaceutical composition is provided comprising the p75NTR protein or a portion thereof, or a fusion protein of the present invention. The fusion protein or pharmaceutical composition described herein may be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitreal, intratumoral, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topically, particularly to the ear, nose, eye, or skin, or by inhalation. In another embodiment, the delivery is of a nucleic acid encoding a drug, for example a nucleic acid encoding a molecule of the present invention is delivered.
[0109] Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical, intraarticular, or subcutaneous administration. Preferably, the compositions are administered parenterally.
[0110] The pharma- ceutically acceptable carrier or vehicle may be particulate, so that the composition is, for example, in tablet or powder form. The term "carrier" refers to a diluent, adjuvant, or excipient with which the drug antibody conjugate of the present invention is administered. Such pharmaceutical carriers may be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Carriers may be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents may be used. In one embodiment, when administered to animals, the polypeptide or composition of the present invention and the pharma- ceutically acceptable carrier are sterile. Water is a preferred carrier when the drug antibody conjugate of the present invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions may also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0111] The pharmaceutical composition may be in the form of a liquid, such as a solution, syrup, solution, emulsion or suspension. The liquid may be useful for oral administration or for delivery by injection, infusion (e.g., IV infusion), or subcutaneously.
[0112] When intended for oral administration, the compositions may be in solid or liquid form, with semi-solid, semi-liquid, suspension and gel forms being included within the forms considered herein as either solid or liquid.
[0113] As a solid composition for oral administration, the composition can be formulated in the form of powder, granules, compressed tablets, pills, capsules, chewing gum, wafers, etc. Such solid compositions typically contain one or more inert diluents. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose, or dextrin; disintegrants such as alginic acid, sodium alginate, corn starch, etc.; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; flavors such as peppermint, methyl salicylate, or orange flavor, and colorants. When the composition is in the form of a capsule (e.g., a gelatin capsule), it can contain liquid carriers such as polyethylene glycol, cyclodextrin, or fatty oils in addition to the above-mentioned types of materials.
[0114] When intended for oral administration, the composition may contain one or more of a sweetener, a preservative, a dye / colorant, and a flavor enhancer. In a composition for administration by injection, one or more of a surfactant, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffer, a stabilizer, and an isotonic agent may also be included.
[0115] The composition may be in the form of one or more dosage units.
[0116] In certain embodiments, it may be desirable to administer the compositions locally to the area in need of treatment or by intravenous injection or infusion.
[0117] The amount of the polypeptide, Fc domain or pharmaceutical composition described herein that is effective / active in treating a particular disease or condition will depend on the nature of the disease or condition and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays may be optionally used to help identify optimal dosage ranges. The exact dose to be used in the composition will also depend on the route of administration and the severity of the disease or condition and should be determined according to the physician's judgment and each patient's circumstances. Factors such as age, body weight, sex, diet, time of administration, excretion rate, condition of the host, drug combinations, reaction sensitivities, and severity of the disease should be taken into account.
[0118] Typically, this amount is at least about 0.01% of the polypeptide of the present invention by weight of the composition. When intended for oral administration, this amount can vary from about 0.1% to about 80% by weight of the composition. A preferred oral composition may contain about 4% to about 50% of the polypeptide of the present invention by weight of the composition.
[0119] The composition can be prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the polypeptide of the invention.
[0120] For administration by injection, the composition may typically comprise about 0.1 mg / kg to about 250 mg / kg of the animal's body weight, preferably 0.1 mg / kg to about 20 mg / kg of the animal's body weight, and more preferably about 1 mg / kg to about 10 mg / kg of the animal's body weight. In one embodiment, the composition is administered at a dose of about 1 to 30 mg / kg, e.g., about 5 to 25 mg / kg, about 10 to 20 mg / kg, about 1 to 5 mg / kg, or about 3 mg / kg. Dosing schedules may vary, for example, from once a week to once every 2, 3, 4 weeks or more.
[0121] Treatment can be, for example, once a month or once every two months, which has advantages over daily dosing as it improves compliance and minimizes stress to the animal.
[0122] As used herein, "treat", "treating" or "treatment" refers to inhibiting or alleviating a disease or disorder. For example, treatment can include postponing the onset of a disease or symptoms associated with a disease and / or reducing the severity of such symptoms that would or are expected to occur with the disease. These terms include amelioration of existing symptoms, prevention of additional symptoms, and amelioration or prevention of the underlying causes of such symptoms. Thus, these terms indicate that a beneficial result is imparted to at least some of the mammalian, e.g., canine, patients being treated. Many medical treatments are effective in some, but not all, patients who receive the treatment.
[0123] The term "subject" or "patient" refers to an animal, preferably a companion animal, particularly a dog or cat, who is the object of treatment, observation, or experiment.
[0124] In another aspect, the present invention relates to the use of a p75NTR protein or a portion thereof, a fusion protein or a pharmaceutical composition as described herein in the treatment or prevention of a disease. In another aspect, the disclosure relates to the use of a polypeptide, an Fc domain or a pharmaceutical composition as described herein in the manufacture of a medicament for the treatment or prevention of a disease as listed herein. The present invention relates to a method of treating a disease in a subject, comprising an effective amount of a polypeptide, an Fc domain or a pharmaceutical composition as described herein.
[0125] For example, the disease is an NGF-associated disorder.
[0126] In one embodiment, the NGF-related disorder is selected from the group consisting of cardiovascular disease, atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, pain, and inflammation. In one embodiment, the NGF-related disorder includes pain. In one embodiment, the pharmaceutical composition is used to treat pain. In one embodiment, the pharmaceutical composition is used to treat pain, and the type of pain is selected from osteoarthritis pain, rheumatoid arthritis pain, surgery and post-operative pain, incision pain, systemic inflammatory pain, cancer pain, traumatic pain, neuropathic pain, neuralgia, diabetic neuropathy pain, pain associated with rheumatic disease, pain associated with musculoskeletal disease, visceral pain, and gastrointestinal pain. In one embodiment, the pain includes osteoarthritis pain. In one embodiment, the pain includes surgery and post-operative pain. In one embodiment, the pain includes cancer pain.
[0127] In one or more embodiments, the p75NTR protein or a portion thereof, fusion protein or pharmaceutical composition of the invention is for use in dogs. In one or more embodiments, the p75NTR protein or a portion thereof, fusion protein or pharmaceutical composition of the invention is for use in cats. In one or more embodiments, the p75NTR protein or a portion thereof, fusion protein or pharmaceutical composition of the invention is for use in horses.
[0128] In one embodiment, the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention is administered with one or more therapeutic agents, for example, a therapeutic agent for treating pain.
[0129] The polypeptides, p75NTR proteins or portions thereof, fusion proteins, or pharmaceutical compositions described herein may be administered at the same time as other therapies or therapeutic compounds or therapies, or at different times, e.g., simultaneously, separately or sequentially.
[0130] The present invention also provides an in vitro or in vivo method for inhibiting NGF activity in a companion animal, comprising administering a p75NTR protein or a portion thereof, a fusion protein, or a pharmaceutical composition of the present invention.
[0131] In one or more embodiments, the invention provides methods of producing a fusion protein of the invention by culturing a host cell of the invention under conditions that result in the production of the fusion protein, and then isolating the fusion protein from the host cell or from the host cell culture medium.
[0132] In another aspect, the present invention provides a kit for treating or preventing, diagnosing, prognosing, or monitoring a disease, comprising the p75NTR protein or a portion thereof, a fusion protein, or a pharmaceutical composition of the present invention. Such a kit may include other components, packaging, and / or instructions.
[0133] In another aspect, the present invention provides the p75NTR protein or a portion thereof, fusion protein, or pharmaceutical composition of the present invention packaged in lyophilized form or in an aqueous medium.
[0134] In another aspect, the p75NTR protein or a part thereof, fusion protein, or pharmaceutical composition of the present invention described herein is used for non-therapeutic purposes, such as diagnostic tests and assays.Thus, the present invention also provides the p75NTR protein and fusion protein described above for use in diagnostic methods for detecting NGF in species known to have or suspected to have NGF-related disorders, particularly dogs and cats.The method for detecting NGF in species known to have or suspected to have NGF-related disorders, particularly dogs and cats, can include exposing a sample from an animal to the labeled protein of the present invention and detecting the labeled protein.It can be used to quantitatively or qualitatively detect NGF in a sample, or to detect the presence of cells expressing NGF.
[0135] Further aspects and embodiments of the present invention will be apparent to those of skill in the art in light of this disclosure, including the following experimental exemplification.
[0136] Unless otherwise defined herein, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by those skilled in the art. The foregoing disclosure provides a general description of the subject matter encompassed within the scope of the present invention, including how to make and use the invention, and the best mode thereof, while the following examples are provided to enable those skilled in the art to practice the invention and further provide a complete written description thereof. However, those skilled in the art will understand that the details of these examples should not be read as limiting the invention. The scope of the present invention should be understood from the claims appended to this disclosure and their equivalents. Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.
[0137] All documents referred to herein are incorporated by reference in their entirety, including any references to gene accession numbers and references to patent publications.
[0138] "And / or," as used herein, should be considered as a specific disclosure of each of the two particular features or components with or without the other. For example, "A and / or B" should be considered as a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were individually described herein. Unless the context dictates otherwise, the above feature descriptions and definitions are not limited to any particular aspect or embodiment of the present invention, but apply equally to all aspects and embodiments described.
[0139] The invention is further illustrated by the following non-limiting examples. EXAMPLES
[0140] method: 1. Protein constructs and CHO transfection / expression (Figure 1) For protein production, DNA constructs were generated encoding chimeric Fc fusion proteins containing the selected canine IgG constant region (between the hinge and C-terminus) fused to the extracellular domain of canine p75 lacking the predicted O-glycosylation-rich stalk region and α- and γ-secretase sites.
[0141] The amino acid sequences of PetML119 (SEQ ID NO: 11) and PetML122 (SEQ ID NO: 13) are shown in Figure 1. An alignment of partial dog, cat, bovine and horse p75 sequences is shown in Figure 2.
[0142] Both canine IgG-B Fc domain and p75 extracellular domain (residues 31-194 from UniProtKB-J9PAM0) were codon optimized and synthesized by GeneArt (Thermo Fisher). Both genes were PCR amplified using Q5 high fidelity DNA polymerase (using specific primers containing overlapping regions to allow assembly) and assembled into mammalian expression vectors PetML119 (Fc-Bwt) and PetML122 (Fc-B-YTE with mutated residues Y252-T254-E256 using EU numbering) using NEBuilder HIFI DNA Assembly (New England Biolabs). In the expression vectors, the fusion protein chain and the antibiotic resistance gene expression unit are flanked by DNA transposon piggyBac terminal inverted repeats, which mediate stable integration into host cells in the presence of piggyBac transposase. Both expression vectors also contain a puromycin resistance cassette located within the piggyBac terminal repeats to facilitate selection for stable integration. To generate stable expression cell lines, PetML119 or PetMl122 was transfected into a suitable mammalian cell line, such as CHO cells, along with PiggyBac transposase, followed by puromycin selection at 10-30 μg / ml for at least 8-10 days. For fusion protein production, 1 × 10 61000μg / mL of selected CHO cells are seeded in 800mL of culture medium (F17 + 4mM l-Gln + 0.3% P188 + 1:500 ACA) and incubated at 32°C, 8% CO2 with shaking at 130 rpm. 2% HyClone Cell Boost 7a supplement + 0.2% HyClone Cell Boost 7b supplement, 2mM glucose are added to the medium from day 4 of overproduction. Culture supernatants are collected on day 10 and protein concentrations are determined using surface plasmon resonance (Biacore 8K, Cytiva Life Sciences) using a Protein A chip. Typically, PetML119 / 122 showed a peak in expression on day 10 of production, reaching approximately 70mg / L.
[0143] 2. Purification of PetML119-122 Cell suspensions from stably transfected clones of PetML119 and PetML122, cultured for at least 7 days as described, were incubated for 10 min in Sartoclear Dynamics® Lab V (SDLV-0500-20C-E) and then filtered using a 0.22 um filter. The clarified supernatant was loaded onto a Mabselect sure LX prepacked 20 mL column (17547402) pre-equilibrated with PBS. The column was washed with 40 mL of PBS (2 CV) and then the fusion protein was eluted using a gradient of 0.1 M glycine pH 2.7 (0-100% in 2 CV). Fractions containing the fusion protein were pooled together and neutralized with 100 mM TRIS pH 8 (final concentration).
[0144] The neutralized fusion protein pool fractions were concentrated to 5 mL and loaded onto a PBS pre-equilibrated HiLoad 16 / 600 Superdex 200 pg (28989335) as a second step purification. Monomeric fractions were pooled (based on retention time of previously analyzed protein standards) and protein concentration was assessed using a NanoDrop™ One (Thermo Scientific™).
[0145] Following the above protocol, approximately 30 mg / L of purified product was obtained.
[0146] PetML119 showed a final recovery of 34 mg / L after a two-step purification (endotoxin and HCP acceptable using standard protocols and buffers).
[0147] PetML122 showed a final recovery of 28 mg / L after a two-step purification (endotoxin and HCP acceptable using standard protocols and buffers).
[0148] 3. HPLC analytical chromatography (Figure 3) The purity of the purified material was assessed using both size exclusion chromatography (SEC) for oligomerization analysis, and cation exchange chromatography (SCX) for charge variant analysis.
[0149] HPLC-SEC chromatography (column: BioResolve SEC mAb 200A, 2.5um column WATERS) was performed using an ACQUITY H-class Bio from WATERS using PBS as the mobile phase with an isocratic flow rate of 0.575mL / min.
[0150] HPLC-SCX chromatography (column: BioResolve SCX mAb column, 3 μm, 4.6 mm × 100 mm) was performed using an ACQUITY H-class Bio from WATERS using MES pH 5 as the mobile phase with a salt gradient and was used to separate the charge variants at a flow rate of 0.9 mL / min.
[0151] 10 uL of each sample was injected into both the H-SEC / H-SCX using the protocol described above. The percentage of monomer species and area (indicative of protein concentration) for each molecule was determined.
[0152] Both PetML119 / 122 showed extremely high purity (more than 99%) by HSEC, and almost no charge variants (presumably corresponding to different glycosylation forms) were observed by HSCX.
[0153] 4. Stress test (Figure 4) Freeze-thaw test: 50 uL aliquots of PetML119 at 5 mg / mL in PBS were prepared and stored in sealed PCR tubes at either 4° C. (1 aliquot per molecule) or −80° C. (3 aliquots per molecule). The −80° C. aliquot was thawed at room temperature for 5 minutes, leaving one aliquot to be returned to −80° C. for storage (1 freeze-thaw). This was repeated two more times (2 and 3 freeze-thaw cycles), and then 10 uL of each sample (including the 4° C. control) was injected onto the H-SEC using the same method as above. The percentage of monomer species and area (indicating protein concentration) was determined for each molecule / freeze-thaw cycle and compared to the reference run (sample stored at 4° C.).
[0154] PetML119 exhibited good resistance to freeze-thawing, with only minor protein loss over three cycles.
[0155] Thermal and chemical stress: 50 uL aliquots of PetML119 at 5 mg / mL in PBS or PBS + 100 mM DTT were prepared and incubated for 30 minutes at different temperatures (25° C., 37° C., 60° C., 70° C. and 95° C.).
[0156] 40 uL of each condition was diluted with 10 uL NuPAGE™ LDS Sample Buffer (NP0007). 10 uL was loaded onto a NuPAGE™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well (NP0302BOX) and run at 120V for 45 minutes. Gels were stained with InstantBlue® Coomassie Protein Stain (ISB1L) (ab119211) for 10 minutes and placed in ddH2O for 1 hour. SDS-PAGE was then acquired using a standard transluminator apparatus.
[0157] The results revealed that PetML119 was highly stable under both temperature and chemical stress, and only showed unfolding when incubated at temperatures above 70°C.
[0158] 5. Protein A binding affinity validation (Figure 5) Purified fusion proteins (PetML119 and PetML122) in PBS were concentrated to 5 mg / mL using a centrifugal concentrator (Sartorious-VS02H22). Protein concentration was assessed using UV absorbance at 280 nm using a NanoDrop™ One (Thermo Scientific™).
[0159] The binding affinity of the fusion proteins to Protein A was assessed using Biacore 8K (Cytiva).
[0160] Briefly, Sensor Chip Protein A (Cytiva) was docked to a Biacore 8K and equilibrated at room temperature for 30 min, and then running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20) was applied to the SPR chip surface.
[0161] Fusion protein dilutions of PetML119 / 122 from 1 uM to 4 nM (6 concentrations at 1:3 dilutions) were prepared in running buffer and kinetics were assessed using single cycle kinetics (Biacore Assay Handbook, Cytiva). Kinetics and / or affinity quantification have been performed using Biacore Insight following standard analytical methods.
[0162] The results show that Protein A binding to PetML122 is slightly affected by the introduced YTE mutations, with a faster dissociation observed compared to PetML119, resulting in lower yields after Protein A purification but comparable protein quality.
[0163] 6. FcRn binding affinity validation (Figure 6) Purified fusion proteins (PetML119 and PetML122) in PBS were concentrated to 5 mg / mL using a centrifugal concentrator (Sartorious-VS02H22). Protein concentration was assessed using UV absorbance at 280 nm using a NanoDrop™ One (Thermo Scientific™).
[0164] The binding affinity of the fusion proteins to fetal Fc receptors was assessed using Biacore 8K (Cytiva).
[0165] Briefly, a CM5 Sensor Chip (Cytiva) was docked to a Biacore 8K and equilibrated at room temperature for 30 min, then running buffer (10 mM HEPES, pH 6, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20) was applied to the SPR chip surface.
[0166] Canine and mouse FcRn-B2M recombinant proteins (Immunitrack, ITF12-ITF08) were diluted to 4 nM (1:2000 dilution from stock) in 10 mM acetate buffer, pH 4.5, and immobilized using a standard amine coupling reaction.
[0167] Fusion protein dilutions were prepared in running buffer from 3 uM to 37 nM (5 concentrations at 1:3 dilution) and kinetics were assessed using multi-cycle kinetics (120 sec association-300 sec dissociation). Kinetics and / or affinity quantification was performed using Biacore Insight following standard analytical methods.
[0168] A 10-fold increase in binding affinity to FcRn was observed for PetML122, confirming that the triple mutant YTE had a positive effect on binding to both the canine and mouse embryonic receptors. Notably, an increase in the dissociation rate was observed.
[0169] 7. Determination of human and rat nerve growth factor (h-rNGF) binding affinity (Figure 7) The purified fusion protein (PetML119) in PBS was concentrated to 5 mg / mL using a centrifugal concentrator (Sartorious-VS02H22). Protein concentration was assessed using UV absorbance at 280 nm using a NanoDrop™ One (Thermo Scientific™).
[0170] The binding affinity of the fusion proteins to human and rat NGF was assessed using Biacore 8K (Cytiva).
[0171] Briefly, a Protein A sensor chip (Cytiva) was docked to a Biacore 8K and equilibrated at room temperature for 30 min, and then running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20) was applied to the SPR chip surface.
[0172] PetML119 was diluted in running buffer at a concentration of 6 nM and immobilized using 90 sec of association at 10 uL / min as a capture step, followed by injection of running buffer to remove unbound product.
[0173] Human and rat NGF (Bio-Techne Ltd-556-NG / CF / 256-GF-100 / CF) were diluted in 100 nM running buffer with a further dilution of 1:2 to 4.68 nM. Kinetics were assessed using multi-cycle kinetics using a capture step method (30 sec association-120 sec dissociation) followed by a regeneration step (0.1 M glycine, pH 2.2, contact time 60 sec, FR 30 uL / min). Kinetic quantification was performed using Biacore Insight following standard analytical methods.
[0174] Results showed subnanomolar KDs for both human and rat NGF with PetML119.
[0175] 8. Intact Mass Analysis Purified fusion proteins (PetML119 and PetML122) in PBS were concentrated to 1 mg / mL using a centrifugal concentrator (Sartorious-VS02H22). Protein concentration was assessed using UV absorbance at 280 nm using a NanoDrop™One (Thermo Scientific™).
[0176] LC-MS analysis was performed on a BioAccord using a BioResolve RP mAb Polyphenyl Column, 450 Å, 2.7 μm, 2.1×50 mm and an ACQUITY UPLC® I-Class Plus from WATERS.
[0177] Briefly, 3 pmol of each fusion protein (diluted in LC-MS grade HO) was injected onto the RP column and the eluate peaks were analyzed by MS. Intact mass analysis showed the presence of multiple species corresponding to different degrees of glycosylation, consistent with that observed by H-SCX.
[0178] The intact molecule appears to be a mixture of molecular species. The observed masses range from 96,158 to 97,836 Da. The mass of the base species (96,158 Da) is consistent with a dimer of Fc fusion amino acids 20 to 241 + 4 glycans, which is consistent with the total number of glycosylation sites predicted in the molecule. The other species are consistent with additional decoration of the glycans.
[0179] 9. Determination of Unfolding and Oligomerization (Figure 4) The purified fusion protein (PetML119) in PBS was concentrated to 3 mg / mL using a centrifugal concentrator (Sartorious-VS02H22). Protein concentration was assessed using UV absorbance at 280 nm using a NanoDrop™ One (Thermo Scientific™).
[0180] Tm and Tagg analysis was performed on UnCle from Unchained labs using standard protocols.
[0181] Briefly, 10 uL of fusion protein was used to determine unfolding and aggregation events during increasing temperature (from 25° C. to 95° C.) As expected from previous results, PetML119 showed no aggregation by 95° C., with a Tm1 of approximately 67° C.
[0182] 10. In vitro NGF inhibition assay (Figure 8) To evaluate the biological activity of our p75 fusion proteins, we used NGF-dependent (TF-1 cell line) cells. The cells are completely dependent on interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) for long-term proliferation. The cells do not respond to interleukin 5 (IL-5). TF-1 cells respond to a variety of other lymphokines and cytokines, such as interleukin 1 (IL-1), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 9 (IL-9), interleukin 11 (IL-11), interleukin 13 (IL-13), stem cell factor (SCF), leukemia inhibitory factor (LIF), and nerve growth factor (NGF).
[0183] The superior sequestration of NGF by this fusion protein results in slower proliferation compared to controls.
[0184] The TF-1 cell line was purchased from ATCC (CRL-2003) and maintained in culture using standard sterile techniques using complete RPMI (10% FBS + 2 mM L-Gln + 10 ng / mL hNGF).
[0185] Two million TF-1 cells were labeled with 2.5uM CFSE cell trace (Invitrogen-C34554) in 1mL RPMI for 30 minutes in the dark only. Cells were then washed twice in complete RPMI medium, counted again, and seeded at 10000 cells / mL in 24-well plates (total volume 1mL per well).
[0186] Dilutions of PetML119 / 122 or control (bezimbetomab-anti-NGF IgG control, irrelevant fusion protein, and RPMI without NGF as negative control, WHO Drug Information, Vol. 32, No. 4, 2018-pg568) were diluted in 100 uL of RPMI medium from 3 uM concentration to 91.25 nM. 100 uL of protein dilutions were added to each well. Briefly, codon-optimized cDNA (for CHO expression) was generated using the published amino acid sequence of bezimbetomab for both the heavy and light chains. Both HC and LC cDNAs were cloned in frame using standard peggy-bac plasmids. CHO were then stably transfected as described above.
[0187] Plates were analyzed after 3 days. Briefly, 1 mL of cell suspension was centrifuged for 5 min at 300 g at room temperature, washed twice with FACS buffer (PBS + 3% FBS + 3 mM EDTA) and finally resuspended in 100 uL of FACS buffer. Cells were acquired using a CytoFLEX flow cytometer using the following parameters (FSC: 20; SSC: 50; FITC: 1; Threshold: 1313131). Cells were gated based on FITC fluorescence (more fluorescence, less proliferation) and the percentage of proliferation inhibition was calculated considering 100% inhibited TF-1 cells cultured in RPMI without NGF and 0% inhibited cells cultured in complete RPMI medium. IC50 values were calculated using Graphpad.
[0188] Both PetML119 / 122 and bedinvetomab were able to inhibit TF-1 proliferation in a dose-dependent manner. [Table 1]
[0189] 11. MIA-induced OA in rats (potency and pK) - Figures 9-12 The efficacy and half-life of PetML119 / 122 was analyzed using a rat model of OA. A detailed protocol is provided below. The model is shown in FIG.
[0190] Induction of arthritis Osteoarthritis was chemically induced by intra-articular (IA) injection of 3 mg sodium iodoacetate (MIA) (in 25 µL saline) into the right hind knee joint of rats given under isoflurane anesthesia. Under anesthesia, ophthalmic ointment was applied to both eyes. The day of IA injection of MIA was counted as day 0.
[0191] Allocation to treatment groups Baseline dynamic weight bearing (DWB) was measured for all rats. Body weight (BW) was also measured at the same time. Rats were anesthetized and MIA was injected into the right knee joint via the middle of the hamstrings approximately perpendicular to the tibia (intra-articular (IA)). The dose level of IA injection of MIA was selected based on previous literature reports in rodents (Bove et al.: Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003 Nov;11(11):821-830). Animals showing significant weight bearing difference between the MIA-injected limb (right) and the healthy limb (left) were assigned to the study. Randomization was performed based on both baseline DWB and BW (two-variable randomization).
[0192] Dynamic Weight Bearing (DWB) Assessment Dynamic weight bearing was assessed using the BioSeb® automated DWB system according to the manufacturer's manual. A 2-minute recording was performed for each rat. Analysis of dynamic weight bearing data was performed offline using BioSeb® software. The system automatically calculated the mass borne by each limb and tail. Body weight was measured for each rat immediately before DWB and for each time of testing. DWB measurements were performed at different time points according to the schedule of the study design. The total distance traveled was also recorded during DWB data analysis.
[0193] Administration of test article Rats in groups 1-2 received an intravenous (IV) injection of vehicle, and rats in groups 3-7 received an IV injection with the test article at the indicated doses once on day 3, as shown in the table below. Rats in group 8 were gavaged with dexamethasone once daily from days 3-21, as shown in the table below.
[0194] Monosodium iodoacetate (MIA)-induced OA rat study using PETML119 / 122 Study design: [Table 2] *Animals in groups 2 to 8 and the reserve group received a single intra-articular (IA) injection of MIA (3 mg / 25 μL saline), and the day of MIA injection was designated as day 0 (right knee joint). IV: intravenous (tail vein); PO: oral gavage; QD - once daily
[0195] Treated animals were observed for any clinical signs throughout the study. DWB was analyzed on days 3, 6, 14, and 21. Joint diameters were measured using calipers on the right knee joint (medial) on days 3, 6, 14, and 21.
[0196] In brief, both PetML119 (at different doses) and 122 (single dose) showed better analgesic effects than the anti-NGF benchmark (bezimbetomab) (Figure 10). They also showed similar activity to daily administration of dexamethasone (weight loss - Figure 11) while not showing the side effects of NSAIDs.
[0197] PK blood from five rats per group was collected on alternate days using standard procedures.
[0198] Serum PK analysis (Figure 12) A sandwich ELISA to quantitate serum levels of the fusion protein was set up as follows. 30uL of capture antibody (mouse anti-dog p75 Ab-->MAB367-SP (Novus Bio)) at 2ug / mL diluted in PBS + 0.1M sodium bicarbonate was immobilized on a half-zone ELISA plate (microplate, 96 well, PS, half-zone, clear, Cat: 675061) overnight at 4℃. · The plate was washed twice with 200uL of blocking solution (PBS+5%DNFM+0.2%Tween20) and blocked with 150uL of blocking solution across all wells for 3 hours at room temperature. Serum from different time points / groups of the rat study were diluted 100-fold in blocking solution (2uL serum + 198uL blocking solution) and 30uL were added to the relevant wells. Standards from PetML119 / 122 were prepared in which the fusion protein was diluted in rat serum from 100ug / mL to 1ng / mL at a 1:5 dilution. The standards were then diluted 100-fold in blocking solution and 30uL were added to the relevant wells. Serum was incubated for 1 hour at room temperature with shaking at 450 rpm. · The plate was washed twice with 200uL of blocking solution, and the detection antibody (SA5-10309 (ThermoFisher)) was diluted 1:40000 in blocking solution, and 30uL was added to each well and left at room temperature for 30 minutes with shaking at 450rpm. · The plate was washed twice with 200uL of blocking solution, and HRP-conjugated antibody (A16035 (ThermoFisher)) was diluted 1:10000 in blocking solution, 30uL was added to each well, and the plate was left at room temperature for 30 minutes while shaking at 450rpm. · The plate was washed twice with 200uL of blocking solution, then twice with 200uL of PBS+0.2% Tween20, and finally 50uL of TMB (TMB Chromogen Solution (for ELISA)-->002023) was added to each well. After 10 minutes, when the standard curve showed saturation at the first two points, the reaction was stopped by adding 50uL of 1M sulfuric acid. All wells were read on a CLARIOstar Plus (BMG LABTECH) using endpoint absorbance at 650 nm and 450 nm. Values were imported into GraphPad and a one-phase decay fit was applied to estimate these half-lives.
[0199] PetML119 from different doses showed similar half-lives (about 70 hours), whereas PetML122 showed an extended half-life (about 10.5 days) (see FIG. 12).
[0200] 12. Pharmacokinetic and pharmacodynamic studies of PetML119 and PetML122 after induction of OA in dogs The safety profile, pharmacokinetic and pharmacodynamic parameters of PetML119 and PetML122 were evaluated after a single intravenous dose of 1.5 mg / kg in dogs after induction of OA (urate crystal model). The study was performed similar to the protocol of Toutian et al., J. Vet. Pharmacol. Therap. 24, 43-55, 2001.
[0201] The study was carried out according to two groups, four periods, four treatments and three sequences. Ten dogs were used.
[0202] Four treatments were tested: A. Positive control (meloxicam) administered orally. B. Negative control (vehicle) intravenous injection. C. PetML119 (1.5 mg / kg) intravenous injection. D. PetML122 (1.5mg / kg) intravenous injection [Table 3]
[0203] Experimental acute synovitis was induced using a reversible urate crystal synovitis model. Sodium urate crystal suspension was prepared at a concentration of 10 mg / mL. General anesthesia was induced via intra-articular injection of propofol. Alternate stifle joints were used for each period.
[0204] Treatment dosing (by intravenous delivery) of vehicle and test articles (PetML119 / PetML122) was administered 3 days (day 3) prior to induction of acute synovitis. Meloxicam treatment was administered immediately prior to induction of acute synovitis (T-0.5 hours). Treatment dosing was designed to obtain maximum treatment effect at the time of maximum induced lameness (i.e., 2-3 hours after induction of acute synovitis). [Table 4] TIFF2024542958000006.tif208154
[0205] safety Each animal was observed at least once daily and no abnormal findings were reported. Hematological parameters were collected and animals were weighed at the time points indicated in Table 4. Blood samples were taken from the jugular or cephalic vein at alternate sites.
[0206] A sandwich ELISA to identify potential anti-drug antibodies (ADA) in serum generated in vivo after treatment with the fusion protein was set up as follows. 30uL of either PetML119 or PetML122 (2 plates) at 2ug / mL diluted in PBS + 0.1M sodium bicarbonate was immobilized on a half-zone ELISA plate (microplate, 96 well, PS, half-zone, clear, Cat: 675061) overnight at 4℃. · Plates were washed twice with 200uL of blocking solution (PBS+5%DNFM+0.2%Tween20) and blocking was performed with 150uL of blocking solution across all wells for 3 hours at room temperature. Serum from different time points / groups of rat / dog studies were diluted 100-fold in blocking solution (2uL serum + 198uL blocking solution) and 30uL was added to the relevant wells. Standards anti-PetML119 / 122 Ab (MAB367 from 1ng / mL) were prepared in 20uL of rat / dog serum + Ab and then diluted in a 1:2 dilution. Standards were then diluted 100-fold in blocking solution and 30uL was added to the relevant wells. Serum was incubated for 1 hour at room temperature with shaking at 450 rpm. · The plate was washed twice with 200uL of blocking solution, and the detection antibody (SA5-10309 (ThermoFisher)) was diluted 1:20000 in blocking solution, and 30uL was added to each well and left at room temperature for 30 minutes with shaking at 450rpm. · The plate was washed twice with 200uL of blocking solution, and HRP-conjugated antibody (A16035 (ThermoFisher)) was diluted 1:10000 in blocking solution, 30uL was added to each well, and the plate was left at room temperature for 30 minutes while shaking at 450rpm. · The plate was washed twice with 200uL of blocking solution, then twice with 200uL of PBS+0.2% Tween20, and finally 50uL of TMB (TMB Chromogen Solution (for ELISA)-->002023) was added to each well. After 10 minutes, when the standard curve showed saturation at the first two points, the reaction was stopped by adding 50uL of 1M sulfuric acid. All wells were read on a CLARIOstar Plus (BMG LABTECH) using endpoint absorbance at 650 nm and 450 nm. Values were imported into GraphPad and a one-phase decay fit was applied to estimate these half-lives.
[0207] result Body weight (FIG. 13a) and hematological parameters were unchanged after PetML119 / PetML122 administration.
[0208] For ADA analysis (Figure 13b), both sera from animals treated with PetML119 / PetML122 showed basal signals comparable to pre-dose controls, indicating that no anti-drug antibodies were generated during the experimental time frame.
[0209] Effectiveness To evaluate the anti-inflammatory and analgesic effects of the test samples, two parameters were investigated: visual lameness score (VLS, determined using a scoring system) and vertical force applied to the ground of the hind paw (VF, expressed in Newtons), measured with a force plate. The force plate was connected to a computer equipped with a digital-analog acquisition card and signal processing software. The force plates (made in eight scales) were inserted into a 50 cm wide and approximately 5 m long path where the dogs were trained to walk on the lead at a constant and similar speed. Efficacy evaluations were performed pre- and post-induction at 1.5, 2.75, 4, 5.25, and 6.5 hours (± 10 min per time point) based on maximum treatment effect and maximum induced lameness.
[0210] lameness ratio VF values were obtained when the limb was placed on the force plate. Dogs passed the path of the force plate at least five times to obtain three interpretable values of the hind limb to calculate the average force of the hind limb. The ratio of the force applied after treatment to the force applied before treatment (baseline force) of the same hind limb was called the "lameness ratio". This parameter describes the force applied by the induced limb in relation to the force applied in the absence of inflammation. If severe lameness without weight bearing was observed during the walking phase, no vertical force was measured and the lameness ratio was set to zero.
[0211] Visual lameness score Dogs were scored for lameness while standing and while walking (approximately 1 minute before scoring) according to a semi-quantitative scale detailed below. [Table 5] [Table 6]
[0212] The composite lameness visual score was the sum of the standing and walking phase scores.
[0213] result After treatment, both PetML119 and PetML122 show improved efficacy over meloxicam, the gold standard for acute pain (Figure 14). Furthermore, PetML119 and PetML122 have the added advantage of only requiring a single dose to prolong pain relief. In contrast, meloxicam or other existing treatments require daily administration, which reduces compliance and increases stress on the animals.
[0214] serum pk analysis Blood samples were collected before and during Period 3 at the following target time points: Following intravenous test article administration at T24, T48, T72 hours (pre-run period 3) and at T168, T336, T504 (pre-run period 4) and T672 hours post-dose. Additional blood samples were collected on days 45 and 60 post-dose.
[0215] The sandwich ELISA for determining pK values is as described in Example 11 above.
[0216] result PetML122 showed an extended half-life (about 19 days) compared to that of PetML119 (about 4 days). See FIG. 15.
[0217] array SEQ ID NO:1: Canine p75NTR protein TIFF2024542958000009.tif44145ECD is underlined
[0218] SEQ ID NO:2: Canine p75NTR nucleic acid sequence TIFF2024542958000010.tif125167 Leader sequence is underlined
[0219] SEQ ID NO: 3: Feline p75NTR protein TIFF2024542958000011.tif52167ECD is underlined
[0220] SEQ ID NO: 4: Cat p75NTR nucleic acid sequence TIFF2024542958000012.tif123167 Leader sequence is underlined
[0221] SEQ ID NO: 5: Horse p75NTR protein TIFF2024542958000013.tif43145ECD is underlined
[0222] SEQ ID NO: 6: Horse p75NTR nucleic acid sequence TIFF2024542958000014.tif12162 TIFF2024542958000015.tif106158 Leader sequence is underlined
[0223] SEQ ID NO: 7: Canine p75NTR protein ECD TIFF2024542958000016.tif26160wt The ECD region includes the stalk region (underlined) and the alpha and gamma secretase cleavage 3' of the stalk region (bold).
[0224] SEQ ID NO: 8: Canine p75NTR ECD nucleic acid sequence AAGGAGGCATGTCCCACTGGCCTGTACACCCACAGCGGCGAGTGCTGCAAAGCCTGCAATCTGGGTGAGGGGGTGGCCCAGCCTTGCGGAGCCAACCAGACCGTGTTGAGCCCTGCCTGGACAGCGTGACCTTCTCGGACGTGGTGAGCGCCACCGAGCCGTGCA AGCCGTGCACCGAGTGCGTGGGGCTGCAGAGCATGTCGCGCCGTGCGTGGAGGCGGACGACGCCGTGTGCCGCTGCGCCTACGGCTACTACCAGGACGAGACGACGGGCCGCTGCGAGGCGTGCCGTGTGTGCGAGGCGGGCTCGGGGCTCGTGTTCTCGTGCCAG GACAGGCAGAACACCGTGTGCGAGGAGTGTCCCGACGGCACGTACTCCGACGAGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTGCGCGAGTGCACGCGCTGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTT GGATTACCCGGTCCACACCCTCAGAGGACTCGGACAGCACCGCCCCAGCACAGAGGAGCCAGAGCTACCTCCAGATCAAGAAATCATAGCCAGCACCATGGCAGATGTGGTGACCACAGTGATGGGCAGCTCTCAGCCTGTAGTGACCCGAGGAACCGCTGACAAC
[0225] SEQ ID NO: 9: Canine ECD of p75NTR stalk region protein WITRSTPSEDSDSTAPSTEEPELPPDQEIIASTMADVVTTVM SEQ ID NO: 10: Canine ECD of p75NTR stalk region nucleic acid sequence TGGATTACCCGGTCCACACCCTCAGAGGACTCGGACAGCACCGCCCCAGCACAGAGGAGCCAGAGCTACCTCCAGATCAAGAAATCATAGCCAGCACCATGGCAGATGTGGTGACCACAGTGATG
[0226] SEQ ID NO: 11: Canine p75NTR ECD-Canine IgGB wt Fc protein fusion TIFF2024542958000017.tif46167 Italics and underlined signal peptide Italics Canine p75-ECD Linker Bold GGGG Underlined Canine Fc-B wt
[0227] SEQ ID NO: 12: Canine p75NTR ECD-Canine IgGB wt Fc nucleic acid sequence TIFF2024542958000018.tif38170 TIFF2024542958000019.tif88167 Leader sequence is underlined
[0228] SEQ ID NO: 13: Canine p75NTR ECD-canine Fc YTE protein fusion TIFF2024542958000020.tif44150 Italics and underlined signal peptide Italics Canine p75-ECD Linker Bold GGGG Underlined Dog Fc-B-YTE
[0229] SEQ ID NO: 14: Canine p75NTR ECD-Fc YTE nucleic acid sequence TIFF2024542958000021.tif26167 TIFF2024542958000022.tif97167 Leader sequence is underlined
[0230] SEQ ID NO:15 IgG-A MEFVLGWVFLVAILQGVQGEVQLVESGGDLVKPAGSLRLSCVASGFTFSNNAMNWVRQAPGKGLQWVAGINSGGSTASADAVKGRFTISRDNAKNTVYLQMNSLTAEDTAVYYCAKV IGNWIATSDLDYWGQGTLVIVSSASTTAPSVFPLAPSCGSTSGSTVALACLVSGYFPEPVTVSWNSGSLTSGVHTFPSVLQSSGLYSLSSMVTVPSSRWPSETFTCNVVHPASNTKVD KPVFNECRCTDTPPCPVPEPLGGPSVLIFPPKPKDILRITRTPEVTCVVLDLGREDPEVQISWFVDGKEVHTAKTQSREQQFNGTYRVVSVLPIEHQDWLTGKEFKCRVNHIDLPPSPI ERTISKARGRAHKPSVYVLPPSPKELSSSDTVSITCLIKDFYPPDIDVEWQSNGQQEPERKHRMTPPQLDEDGSYFLYSKLSVDKSRWQQGDPFTCAVMHETLQNHYTDLSLSHSPGK
[0231] SEQ ID NO:16 IgG-B MEFVLGWVFLVAILQGVQGEVQLVESGGDLVKPAGSLRLSCVASGFTFSNNAMNWVRQAPKGGLQWVAGINSGGSTASADAVKGRFTISRDNAKNTVYLQMSLTAEDTAVYCAKVIGNWIATSDLDYWGQGTLVISSASTTAPSVFPLAPSCGSTGSGSTVALACLVSGYFPEPVTVSWNSGSLTGSGVHTFPSVLQSSGLYSLSSMVTVPSSRWPSETTCNVAHPASTKVDKP VPKRENGRVPRPPDCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFNGTYRVVSVLPIGHQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLIKDFPPDIVEWQSNGQQEPESKYRTTPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQKSLSHPGK
[0232] SEQ ID NO:17 IgG-C MEFVLGWVFLVAILQGVQGEVQLVESGGDLVKPAGSLRLSCVASGFTFSNNAMNWVRQAPKGGLQWVAGINSGGSTASADAVKGRFTISRDNAKNTVYLQMSLTAEDTAVYCAKVIGNWIATSDLDYWGQGTLVSSASTTAPSVFPLAPSCGSQSGSTVALACLVSGYIPEPVTVSWNSGSLTGSGVHTFPSILQSSGLYSLSSMVTVPSSRWPSETFTCNVAHPATNTKVDK PVVKECECCKCNCNNCPCGCGLLGGPSVFIFPPKPKDILVTARTPTVTCVVDLDPENPEVQISWFVDSKQVQTANTQPREEQSNGTYRVVSVLPIGHQDWLSGKQFKCKVNNKALPSPIEEIISKTPGQAHQPNVYVLPPSRDEMSKNTVTLTCLVKDFFPPEIDVEWQSNGQQEPESKYRMTPPPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQKSLSHPGK
[0233] SEQ ID NO:18 IgG-D MEFVLGWVFLVAILQGVQGEVQLVESGGDLVKPAGSLRLSCVASGFTFSNNAMNWVRQAPGKGLQWVAGINSGGSTASADAVKGRFTISRDNAKNTVYLQMNSLTAEDTAVYYCAKV IGNWIATSDLDYWGQGTLVIVSSASSTAPSVFPLAPSCGSTSGSTVALACLVSGYFPEPVTVSWNSGSLTSGVHTFPSVLKSSGLYSLSSMVTVPSSRLPSETFTCNVVHPATNTKVD KPVPKESTCKCISPCPVPESLGGPSVFIFPPKPKDILRITRTPEVTCVVLDLGREDPEVQISWFVDGKEVHTAKTQPREQQFNSTYRVVSVLPIEHQDWLTGKEFKCRVNHIGLPSPI ERTISKARGQAHQPGVYVLPPSPKELSSSDTVTLTCLIKDFFPPEIDVEWQSNGQPEPESKYHTTAPQLDEDGSYFLYSKLSVDKSRWQQGDPFTCAVMHEALQNHYTDLSLSHSPGK
[0234] SEQ ID NO:19 DOGA constant region FNECRCTDTPPCPVPEPLGGPSVLIFPPKPKDILRITRTPEVTCVVLDLGREDPEVQISWFVDGKEVHTAKTQSREQQFNGTYRVVSVLPIEHQDWLTGKEFKCRVNHIDLPSPIE RTISKARGRAHKPSVYVLPPSPKELSSSDTVSITCLIKDFYPPDIDVEWQSNGQQEPERKHRMTPPQLDEDGSYFLYSKLSVDKSRWQQGDPFTCAVMHETLQNHYTDLSLSHSPGK SEQ ID NO:20 DOGB constant region RENGRVPRPPDCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFNGTYRVVSVLPIGHQDWLKGKQFTCKVNNKALPSP IERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQKSLSHSPGK
[0235] SEQ ID NO:21 DOGB-YTE constant region RENGRVPRPPDCPKCPAPEMLGGPSVFIFPPKPKDTLYITREPEVTCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFNGTYRVVSVLPIGHQDWLKGKQFTCKVNNKALPSP IERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQKSLSHSPGK SEQ ID NO:22 DOGC constant region ECECKCNCNNCPCPGCGLLGGPSVFIFPPKPKDILVTARTPTVTCVVVDLDPENPEVQISWFVDSKQVQTANTQPREEQSNGTYRVVSVLPIGHQDWLSGKQFKCKVNNKALPSPI EEIISKTPGQAHQPNVYVLPPSRDEMSKNTVTLTCLVKDFFPPEIDVEWQSNGQQEPESKYRMTPPQLDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQKSLSHSPGK
[0236] SEQ ID NO:23 DOGD constant region ESTCKCISPCPVPESLGGPSVFIFPPKPKDILRITRTPEVTCVVLDLGREDPEVQISWFVDGKEVHTAKTQPREQQFNSTYRVVSVLPIEHQDWLTGKEFKCRVNHIGLPPSPIER TISKARGQAHQPGVYVLPPSPKELSSSDTVTLTCLIKDFFPPEIDVEWQSNGQPEPESKYHTTAPQLDEDGSYFLYSKLSVDKSRWQQGDPFTCAVMHEALQNHYTDLSLSHSPGK SEQ ID NO:24 CAT_IGG1V1 constant region TDHPPGPKPCDCPKCPPPEMLGGPSIFIFPPKPKDTLSISRTPEVTCLVVDLGPDDSDVQITWFVDNTQVYTAKTSPREEQFNSTYRVVSVLPILHQDWLKGKEFKCKVNSKSLPSP IERTISKAKGQPHEPQVYVLPPAQEELSRNKVSVTCLIKSFHPPDIAVEWEITGQPEPENNYRTTPPQLDSDGTYFVYSKLSVDRSHWQRGNTYTCSVSHEALHSHHTQKSLTQSPGK
[0237] SEQ ID NO:25 CAT_IGG1V2 constant region TDHPPGPKPCDCPKCPPPEMLGGPSIFIFPPKPKDTLSISRTPEVTCLVVDLGPDDSDVQITWFVDNTQVYTAKTSPREEQFNSTYRVVSVLPILHQDWLKGKEFKCKVNSKSLPSP IERTISKAKGQPHEPQVYVLPPAQEELSRNKVSVTCLIKSFHPPDIAVEWEITGQPEPENNYRTTPPQLDSDGTYFVYSKLSVDRSHWQRGNTYTCSVSHEALHSHHTQKSLTQSPGK SEQ ID NO:26 CAT_IGG2 constant region KTASTIESKTGEGPKCPVPEIPGAPSVFIFPPKPKDTLSISRTPEVTCLVVDLGPDDSNVQITWFVDNTEMHTAKTRPREEQFNSTYRVVSVLPILHQDWLKGKEFKCKVNSKSLPSA MERTISKAKGQPHEPQVYVLPPTQEELSENKVSVTCLIKGFHPPDIAVEWEITGQPEPENNYQTTPPQLDSDGTYFLYSRLSVDRSHWQRGNTYTCSVSHEALHSHHTQKSLTQSPGK
[0238] SEQ ID NO:27 HORSE_IGHG1 constant region VIKECNGGCPAECLQVGPSVFIFPPKPKDVLMISRTPTVTCVVVDVGHDFPDVQFNWYVDGVETHTATTEPKQEQFNSTYRVVSVLPIQHKDWLSGKEFKCKVNNKALPVER TISKPTGQPREPQVYVLAPHRDELSKNKVSVTCLVKDFYPTDIDIEWKSNGQPEPETKYSTTPAQLDSDGSYFLYSKLTVETNRWQQGTTFTCAVMHEALHNHYTEKSVSKSPGK SEQ ID NO:28 HORSE_IGHG2 steady region CVLSAEGVIPIPSVPKPQCPPYTHSKFLGGPSVFIFPPNPKDALMISRTPVVTCVVVNLSDQYPDVQFSWYVDNTEVHSAITKQREAQFNSTYRVVSVLPIQHQDWLSGKEFKCSVTNVGV PQPISRAISRGKGPSRVPQVYVLPPHPDELAKSKVSVTCLVKDFYPPDISVEWQSNRWPELEGKYSTTPAQLDGDGSYFLYSKLSLETSRWQQVESFTCAVMHEALHNHFTKTDISESLGK
[0239] SEQ ID NO:29 HORSE_IGHG3 TTPPCPCECPKCPAPELLGGPSVFIFPPKDVLMITRTPEVTCLVVDVSHDSSDVLFTWYVDGTEVKTAKTMPNEEQNNSTYRVVSVLRIQHQDWLNGKKFKCKVNNQALPAPVE RTISKATGQTRVPQVYVLAPHPDELSKNKVSVTCLVKDFLPTDITVEWQSNEHPEPEGKYRTTEAQKDSDGSYFLYSKLTVETDRWQQGTTFTCVVMHEALHNHVMQKNVSHSPGK SEQ ID NO:30 HORSE_IGHG4 constant region VIKECNGGCPAECLQVGPSVFIFPPKPKDVLMISRTPTVTCVVVDVGHDFPDVQFNWYVDGVETHTATTEPKQEQFNSTYRVVSVLPIQHKDWLSGKEFKCKVNNKALPVER TISKPTGQPREPQVYVLAPHRDELSKNKVSVTCLVKDFYPTDIDIEWKSNGQPEPETKYSTTPAQLDSDGSYFLYSKLTVETNRWQQGTTFTCAVMHEALHNHYTEKSVSKSPGK
[0240] SEQ ID NO:31 HORSE_IGHG5 steady region VVKGSPCPKCPAPELPGGPSVFIFPPKPKDVLKISRKPEVTCVVVDLGHDDPDVQFTWFVDGVETHTATTEPKEEQFNSTYRVVSVLPIQHQDWLSGKEFKCSVTNKALPVER TTSKAKGQLRVPQVYVLAPHPDELAKNTVSVTCLVKDFYPPEIDVEWQSNEHPEPEGKYSTTPAQLNSDGSYFLYSKLSVETSRWKQGESFTCGVMHEAVENHYTQKNVSHSPGK SEQ ID NO:32 >HORSE_IGHG6 steady region KEPCCCPKCPGRPSVFIFPPNPKDTLMISRTPEVTCVVVDVSQENPDVKFNWYVDGVEAHTATTKAKEKQDNSTYRVVSVLPIQHQDWRRGKEFKCKVNNRALPAPVERTIT KAKGELQDPKVYILAPHREEVTKNTVSVTCLVKDFYPPDINVEWQSNEEPEPEVKYSTTPAQLDGDGSYFLYSKLTVETDRWEQGESFTCVVMHEAIRHTYRQKSITNFPGK
[0241] SEQ ID NO:33 HORSE_IGHG7 steady region VIKECGGCPTCPECLSVGPSVFIFPPKPKDVLMISRTPTVTCVVVDVGHDFPDVQFNWYVDGVETHTATTEPKQEQNNSTYRVVSILAIQHKDWLSGKEFKCKVNNQALPAPVQK TISKPTGQPREPQVYVLAPHRDELSKNKVSVTCLVKDFYPTDIDIEWKSNGQPEPETKYSTTPAQLDSDGSYFLYSKLTVETNRWQQGTTFTCAVMHEALHNHYTEKSVSKSPGK
[0242] SEQ ID NO:34 Portion of canine ECD used in fusion construct (without the stalk and without the alpha and gamma secretase cleavage 3' of the stalk region) KEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDRQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIP KEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDRQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIP SEQ ID NO:35 Canine p75NTR ECD nucleic acid sequence used in the fusion construct (without the stalk and without the alpha and gamma secretase cleavage 3' of the stalk region) AAGGAGGCATGTCCCACTGGCCTGTACACCCACAGCGGCGAGTGCTGCAAAGCCTGCAATCTGGGTGAGGGGGTGGCCCAGCCTTGCGGAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGACA GCGTGACCTTCTCGGACGTGGTGAGCGCCACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTGCAGAGCATGTCGCGCCGTGCGTGGAGGCGGACGACGCCGTGTGCCGCTGCGCCTAC GGCTACTACCAGGACGAGACGACGGGCCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGGCTCGTGTTCTCGTGCCAGGACAGGCAGAACACCGTGTGCGAGGAGTGTCCCGACGGCA CGTACTCCGACGAGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTGCGCGAGTGCACGCGCTGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGT
[0243] SEQ ID NO: 36: Bovine p75NTR protein TIFF2024542958000023.tif21167 TIFF2024542958000024.tif20167ECD is underlined
[0244] SEQ ID NO: 37: Bovine p75 NTR nucleic acid
[0245] SEQ ID NO: 38: Feline p75NTR protein ECD KEACPTGLFTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDRQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLECTRWADAECEEIPGRWITRSTPSEGSDST APSTEEPEVPPEQDLIASTVADVVTTVMGSSQPVVTRGTADN
[0246] SEQ ID NO: 39: Feline p75NTR ECD-feline IgG1 wt Fc protein fusion TIFF2024542958000025.tif16167 TIFF2024542958000026.tif20167 Italics and underlined signal peptide Italics Cat p75-ECD Linker Bold GGGG Underlined: Feline Fc-IgG1
[0247] SEQ ID NO: 40: Feline p75NTR ECD-Feline IgG1 wt Fc nucleic acid sequence TIFF2024542958000027.tif87167
[0248] SEQ ID NO: 41: Feline IgG3 LPPCKCPKCPVPEIPGGPSVFIFPPKPKDTLSISRTPEVTCLVVDLGPDDSNVQITWFVDNTEMHTAKTRPREEQFNSTYRVVSVLPIVHQDWLTGKEFKCKVNSKALPSAIER TISKAKGQPHEPQVYVLPPAQEELSENKVCVTCLIKGFYPPDIAVEWEITGQPEPENNYRTTPPQLDSDGTYFVYSRLSMDRSRWQSGNTYTCSVSHEALHSHHTQKSLTQSPGK * * *
[0249] Although the preferred embodiments of the invention have been described in detail above, it should be understood that the invention defined by the above paragraphs is not limited to the specific details set forth in the above description, since many obvious variations thereof are possible without departing from the spirit or scope of the invention.
Claims
1. An isolated companion animal p75NTR protein or portion thereof.
2. 2. The isolated companion animal p75NTR protein or portion thereof of claim 1, wherein the companion animal is a cat, a dog, a pig, a cow or a horse.
3. 3. The isolated companion animal p75NTR protein or portion thereof of claim 2, wherein the companion animal is a dog.
4. 3. The isolated companion animal p75NTR protein or portion thereof of claim 2, wherein the companion animal is a cat.
5. 4. The isolated companion animal p75NTR protein or portion thereof of claim 3, comprising SEQ ID NO:
1.
6. 5. The isolated companion animal p75NTR protein or portion thereof of claim 4, comprising SEQ ID NO:
3.
7. 2. An isolated companion animal p75NTR protein or portion thereof according to the preceding claims, comprising the extracellular domain or a portion thereof.
8. The isolated companion animal p75NTR extracellular domain of claim 7, wherein the companion animal is a dog and comprises SEQ ID NO:
7.
9. The isolated companion animal p75NTR extracellular domain of claim 7, wherein the companion animal is a cat and comprises SEQ ID NO:
38.
10. 10. An isolated nucleic acid encoding the companion animal p75NTR protein or a portion thereof of any one of claims 1-9.
11. The isolated nucleic acid of claim 10, wherein the companion animal is a dog and comprises SEQ ID NO:
2.
12. The isolated nucleic acid of claim 10, wherein the companion animal is a cat and comprises SEQ ID NO:
4.
13. A vector comprising the nucleic acid according to any one of claims 10 to 12.
14. A host cell comprising a nucleic acid according to any one of claims 10 to 12 or a vector according to claim 13.
15. A fusion protein comprising an isolated companion animal p75NTR extracellular domain or a portion thereof and a half-life extending moiety.
16. 16. The fusion protein of claim 15, wherein the half-life extending moiety is selected from an Fc domain, a serum albumin binding agent, or PEG.
17. The fusion protein of claim 16, wherein the half-life extending moiety is a wild-type or mutant Fc domain.
18. The fusion protein according to any one of claims 15 to 17, wherein the half-life extending portion is an Fc domain, and the p75NTR extracellular domain or a portion thereof and the Fc domain are linked via a linker.
19. The fusion protein of claim 18 , wherein the linker is a peptide linker.
20. The peptide linker is (G 4 S) n 20. The fusion protein of claim 19, wherein n is 1 to 4.
21. The fusion protein of any one of claims 15 to 20, wherein the companion animal is a cat, a dog or a horse.
22. The fusion protein of claim 21 , wherein the companion animal is a dog.
23. The fusion protein of claim 22, wherein the p75NTR extracellular domain comprises SEQ ID NO:7, or a portion thereof, such as SEQ ID NO:
34.
24. The fusion protein of any one of claims 15 to 23, wherein the Fc domain is a canine Fc domain.
25. 25. The fusion protein of claim 24 comprising SEQ ID NO: 11 or 13.
26. The fusion protein of claim 21 , wherein the companion animal is a cat.
27. The fusion protein of claim 26, wherein the p75NTR extracellular domain comprises SEQ ID NO:
38.
28. 28. The fusion protein of claim 27 comprising SEQ ID NO:
39.
29. A nucleic acid encoding a fusion protein according to any one of claims 15 to 28.
30. A vector comprising the nucleic acid of claim 29.
31. 31. A host cell comprising the nucleic acid of claim 29 or the vector of claim 30.
32. A pharmaceutical composition comprising an isolated companion animal p75NTR protein according to any one of claims 1-9, or a fusion protein according to any one of claims 15-28.
33. 33. A method for treating an NGF-related disorder in a companion animal, comprising administering an isolated companion animal p75NTR protein according to any one of claims 1-9, a fusion protein according to any one of claims 15-28, or a pharmaceutical composition according to claim 32.
34. 33. Use of an isolated companion animal p75NTR protein according to any one of claims 1 to 9, a fusion protein according to any one of claims 15 to 28, or a pharmaceutical composition according to claim 32 in the treatment of an NGF-related disorder in a companion animal.
35. 35. The method of claim 33 or the use of claim 34, wherein the NGF-related disorder is cardiovascular disease, atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, pain, and inflammation.
36. 36. The method or use of claim 35, wherein the NGF-related disorder is a pain-related disorder.
37. 37. The method or use of claim 36, wherein the pain is selected from osteoarthritis pain, rheumatoid arthritis pain, surgical and post-operative pain, incisional pain, systemic inflammatory pain, cancer pain, pain due to trauma, neuropathic pain, neuralgia, diabetic neuropathic pain, pain associated with rheumatic diseases, pain associated with musculoskeletal diseases, visceral pain, and gastrointestinal pain.
38. 33. A method for inhibiting NGF activity in a companion animal, comprising administering an isolated companion animal p75NTR protein according to any one of claims 1-9, a fusion protein according to any one of claims 15-28, or a pharmaceutical composition according to claim 32.
39. 39. The method or use of claim 36 or 37, or the method of claim 38, comprising administration of a second compound which treats pain.
40. A kit comprising an isolated companion animal p75NTR protein according to any one of claims 1 to 9, a fusion protein according to any one of claims 15 to 28, or a pharmaceutical composition according to claim 32, and optionally instructions for use.
Citation Information
Patent Citations
P75NTR -FC fusion protein
WO2016146841A1
NGF antagonists for medical use
WO2020191289A1
